Page last updated: 2024-08-02 00:05:42
lumefantrine
Description
Lumefantrine: A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION). [MeSH]
lumefantrine : A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6437380 |
| CHEMBL ID | 38827 |
| SCHEMBL ID | 127331 |
| CHEBI ID | 156095 |
| MeSH ID | M0267388 |
Synonyms (104)
| Synonym |
|---|
| AC-4542 |
| lumefantrine (jan/usp/inn) |
| D03821 |
| 82186-77-4 |
| lumefantrine |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)- |
| dl-benflumelol |
| (+-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol |
| benflumetol |
| (+-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol |
| c30h32cl3no |
| NCGC00167490-01 |
| cpg-56695 |
| benflumelol |
| lumefantrinum |
| gnf-pf-1971 , |
| CHEMBL38827 |
| (+/-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol |
| DB06708 |
| chebi:156095 , |
| 2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9h-fluoren-4-yl]-ethanol |
| 2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(z)-ylidene]-9h-fluoren-4-yl}-ethanol |
| 2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl]ethanol |
| 2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol |
| HMS3260F22 |
| dtxsid3046663 , |
| cas-82186-77-4 |
| dtxcid1026663 |
| tox21_112491 |
| AKOS015918181 |
| S3746 |
| 2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]fluoren-4-yl]ethanol |
| f38r0jr742 , |
| unii-f38r0jr742 |
| lumefantrine [usan:inn:ban] |
| (z)-2-(dibutylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl)ethanol |
| MLS003899226 |
| smr002543514 |
| STL373579 |
| coartem component lumefantrine |
| 2-dibutylamino-1-(2,7-dichloro-9-(1-(4-chlorophenyl)meth-(z)-ylidene)-9h-fluoren-4-yl)ethanol |
| lumefantrine [usan] |
| lumefantrine [usp monograph] |
| lumefantrine [orange book] |
| lumefantrine [hsdb] |
| lumefantrine [usp-rs] |
| lumefantrine [mi] |
| lumefantrine [mart.] |
| lumefantrine [inn] |
| lumefantrine [who-ip] |
| lumefantrine [who-dd] |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)- |
| lumefantrine [vandf] |
| lumefantrine component of coartem |
| 120583-69-9 |
| lumefantrine [jan] |
| lumefantrinum [who-ip latin] |
| (+/-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-.alpha.((dibutylamino)methyl)fluorene-4-methanol |
| CCG-221574 |
| SCHEMBL127331 |
| BBL030364 |
| 2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9h-fluoren-4-yl]ethan-1-ol |
| NCGC00167490-03 |
| tox21_112491_1 |
| HS-0098 |
| tox21_500270 |
| CS-5130 |
| NCGC00260955-01 |
| HY-B0803 |
| 120583-71-3 |
| ZUV4B00D9P , |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (9z)-(-)- |
| d-benflumelol |
| lumefantrine, (+)- |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (9z)-(+)- |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)-(+)- |
| 01NP22J3SV , |
| 120583-70-2 |
| l-benflumelol |
| lumefantrine, (-)- |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)-(-)- |
| (9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-alpha-[(dibutylamino)methyl]-9h-fluoren-4-methanol |
| L0256 |
| mfcd05662268 |
| lumefruntrine |
| (9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-alpha-[(dibutylamino)methyl]-9h-fluorene-4-methanol |
| lumefantrine, united states pharmacopeia (usp) reference standard |
| (1rs)-2-(dibutylamino)-1-[(z)-2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl]ethanol |
| unii-01np22j3sv |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)-(-)- |
| unii-zuv4b00d9p |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (9z)-(+)- |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (9z)-(-)- |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)-(+)- |
| (z)-2-(dibutylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl)ethan-1-ol |
| Q904464 |
| AMY22191 |
| gtpl9969 |
| NCGC00167490-05 |
| benflumetol, cpg-56695 |
| 9h-fluorene-4-methanol, 2,7-dichloro-9-[(4-chlorophenyl)methylene]-?-[(dibutylamino)methyl]-, (9z)- (9ci); 9h-fluorene-4-methanol, 2,7-dichloro-9-[(4-chlorophenyl)methylene]-?-[(dibutylamino)methyl]-, (z)-; benflumelol; benflumetol; lumefantrine; dl-benfl |
| lumefantrine for system suitability |
| CS-0368446 |
| EN300-781170 |
Roles (1)
| Role | Description |
|---|
| antimalarial | A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. |
Drug Classes (4)
| Class | Description |
|---|
| tertiary amine | A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. |
| monochlorobenzenes | Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| fluorenes | An ortho-fused polycyclic arene in which the skeleton is composed of two benzene rings ortho-fused to cyclopentane. |
Protein Targets (38)
Potency Measurements
Inhibition Measurements
Bioassays (146)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
ISSN: 1095-9203 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID558832 | Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID497995 | AUC (0-infinity) in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
ISSN: 1098-6596 | Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. |
| AID582696 | Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID562112 | Selectivity ratio of IC50 for Plasmodium falciparum 3D7 to IC50 for multidrug-resistant Plasmodium falciparum VS/1 | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
ISSN: 1098-6596 | In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid. |
| AID558836 | Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID564240 | Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 and wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID564242 | Antiplasmodial activity against Plasmodium falciparum harboring wild type pfcrt-76 and wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID558837 | Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID1168868 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
ISSN: 1464-3391 | Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives. |
| AID582702 | Drug concentration in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether measured after 7 days by two-compartment populati | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID1168869 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
ISSN: 1464-3391 | Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives. |
| AID558841 | Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582709 | Apparent volume of distribution in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharma | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID582700 | Drug concentration in pregnant human with uncomplicated multidrug-resistant Plasmodium falciparum malaria infection at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID240820 | Inhibitory concentration against IKr potassium channel | 2004 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
ISSN: 0960-894X | The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. |
| AID564239 | Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID1593291 | Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID582704 | Terminal elimination half-life in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmac | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID497987 | Half life in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
ISSN: 1098-6596 | Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. |
| AID564232 | Antiplasmodial activity against Plasmodium falciparum clinical isolate after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID519195 | Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804 | Determinants of in vitro drug susceptibility testing of Plasmodium vivax. |
| AID558844 | Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582694 | Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID558840 | Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID562110 | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
ISSN: 1098-6596 | In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid. |
| AID558834 | Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582697 | Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 4 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID643459 | Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as decrease in parasitemia at 18 mg/kg, po administered 24 hrs post-infection measured after 3 days by Giemsa microscopy relative to vehicle treated control | 2012 | Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
ISSN: 1520-4804 | Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine. |
| AID519197 | Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804 | Determinants of in vitro drug susceptibility testing of Plasmodium vivax. |
| AID529905 | Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
ISSN: 1098-6596 | First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros. |
| AID558829 | Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID1593290 | Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID519196 | Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804 | Determinants of in vitro drug susceptibility testing of Plasmodium vivax. |
| AID449703 | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID547315 | Antimalarial activity against Plasmodium falciparum | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
ISSN: 1098-6596 | In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. |
| AID582706 | Absorption rate constant in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinet | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID1593253 | Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID511252 | Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID582705 | Volume of distribution at steady state in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID558830 | Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID511251 | Antimicrobial activity against Plasmodium falciparum by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID582698 | Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID564235 | Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID564238 | Antiplasmodial activity against Plasmodium falciparum harboring wild type and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID158865 | Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. |
| AID558838 | Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID449705 | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID643456 | Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as host survival at 18 mg/kg, po administered 24 hrs post-infection (Rvb = 6.8 days) | 2012 | Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
ISSN: 1520-4804 | Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine. |
| AID1688324 | Antimalarial activity against Plasmodium falciparum 3D7A asexual forms assessed as inhibition of [G-3H]hypoxanthine uptake incubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by liquid scintillation spectrometry | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188ISSN: 1768-3254 | Current progress in antimalarial pharmacotherapy and multi-target drug discovery. |
| AID511255 | Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID576612 | Inhibition of human ERG | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
ISSN: 1768-3254 | Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. |
| AID582710 | Clearance in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID582701 | Drug concentration in pregnant human patient with reappeared uncomplicated multidrug-resistant Plasmodium falciparum malaria infection at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID635308 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2mef infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by beta liquid scintillation counting method | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
ISSN: 1464-3391 | Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. |
| AID558835 | Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID558827 | Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID558847 | Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582708 | Intercompartmental clearance in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacok | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID582703 | AUC (0 to infinity) in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic mo | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID1593288 | Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID564230 | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID1168867 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
ISSN: 1464-3391 | Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives. |
| AID748941 | Terminal half life in human | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
ISSN: 1464-3405 | Recent advances in malaria drug discovery. |
| AID582695 | Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 4 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID564234 | Antiplasmodial activity against Plasmodium falciparum harboring wild type and mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID564237 | Antiplasmodial activity against Plasmodium falciparum harboring mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID558843 | Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID564241 | Antiplasmodial activity against Plasmodium falciparum harboring wild type pfcrt-76 and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID158864 | Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. |
| AID497988 | Cmax in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
ISSN: 1098-6596 | Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. |
| AID449706 | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID1445968 | Inhibition of human ERG by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
ISSN: 1520-4804 | 3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally. |
| AID519198 | Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
ISSN: 0066-4804 | Determinants of in vitro drug susceptibility testing of Plasmodium vivax. |
| AID558845 | Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID564236 | Antiplasmodial activity against Plasmodium falciparum harboring wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID1649432 | Antimalarial activity against Plasmodium falciparum clinical isolates measured after 72 hrs by SYBR green dye based fluorescence assay | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
ISSN: 1520-4804 | Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. |
| AID449704 | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID582711 | Cmax in venous plasma of pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured on 7 days by two-compartment populati | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID511254 | Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID511253 | Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID558833 | Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID558828 | Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID558831 | Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID564231 | Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum 3D7 after 18 hrs by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ISSN: 1098-6596 | In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. |
| AID1593289 | Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID562111 | Antiplasmodial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine incorporation assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
ISSN: 1098-6596 | In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid. |
| AID558842 | Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID157697 | Anti-malarial activity against Plasmodium falciparum Dd2 | 2003 | Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. |
| AID157697 | Anti-malarial activity against Plasmodium falciparum Dd2 | 2003 | Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. |
| AID1593287 | Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID497976 | AUC (0-120 hrs) in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisin administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
ISSN: 1098-6596 | Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. |
| AID158715 | Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay | 2003 | Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties. |
| AID558826 | Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582707 | Apparent peripheral volume of distribution in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment popula | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID748936 | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum W2 infected in human erythrocytes | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
ISSN: 1464-3405 | Recent advances in malaria drug discovery. |
| AID1593296 | Inhibition of Plasmodium falciparum cytochrome b-c1 | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
ISSN: 1520-4804 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials. |
| AID158852 | Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution | 2003 | Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. |
| AID158852 | Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution | 2003 | Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
ISSN: 0960-894X | Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. |
| AID511256 | Antimicrobial activity against Plasmodium falciparum harboring mdr1 N86Y/D1246Y/Y184F mutant gene by ELISA | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
ISSN: 1098-6596 | In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. |
| AID582712 | Tlag in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID582693 | Cmax in capillary plasma of pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured on 7 days by two-compartment popul | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID558839 | Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID558846 | Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
ISSN: 1098-6596 | Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. |
| AID582699 | Drug concentration in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
ISSN: 1098-6596 | Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. |
| AID555962 | Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
ISSN: 1098-6596 | In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60ISSN: 1873-3913 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
ISSN: 1552-454X | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2022 | Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1
ISSN: 1475-6374 | |
| AID602156 | Novartis GNF Liver Stage Dataset: Malariabox Annotation | 2011 | Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
ISSN: 1095-9203 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. |
Research
Studies (471)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (4.25) | 18.2507 |
| 2000's | 134 (28.45) | 29.6817 |
| 2010's | 243 (51.59) | 24.3611 |
| 2020's | 74 (15.71) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 123 (25.26%) | 5.53% |
| Reviews | 34 (6.98%) | 6.00% |
| Case Studies | 25 (5.13%) | 4.05% |
| Observational | 4 (0.82%) | 0.25% |
| Other | 301 (61.81%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| n,n-dimethylaniline | | dimethylaniline;
tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trimethylamine | | methylamines;
tertiary amine | Escherichia coli metabolite;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bepridil | | pyrrolidines;
tertiary amine | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butenafine | | naphthalenes;
tertiary amine | antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clomiphene | | tertiary amine | estrogen antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicyclomine | | carboxylic ester;
tertiary amine | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenylpyraline | | piperidines;
tertiary amine | cholinergic antagonist;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(6),n(6)-dimethyladenine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxylamine | | pyridines;
tertiary amine | anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alverine | | tertiary amine | antispasmodic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promazine | | phenothiazines;
tertiary amine | antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triallate | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diethylpropion | | aromatic ketone;
tertiary amine | appetite depressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n,n-dimethylcyclohexylamine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tripropylamine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tributylamine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deanol | | ethanolamines;
tertiary amine | curing agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triethylamine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bufotenin | | tertiary amine;
tryptamine alkaloid | coral metabolite;
hallucinogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eptc | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pebulate | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-quinuclidinol | | quinuclidines;
secondary alcohol;
tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s,n,n'-tripropylthiocarbamate | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butylate | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azatadine | | benzocycloheptapyridine;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difenoxin | | nitrile;
piperidinemonocarboxylic acid;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naftifine | | allylamine antifungal drug;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1-phenylcyclohexyl)pyrrolidine | | pyrrolidines;
tertiary amine | general anaesthetic;
hallucinogen;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| disperse blue 124 | | 1,3-thiazoles;
monoazo compound;
tertiary amine | allergen;
dye;
hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lupanine | | delta-lactam;
quinolizidine alkaloid;
tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenpropidine | | piperidines;
tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lobeline | | aromatic ketone;
piperidine alkaloid;
tertiary amine | nicotinic acetylcholine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| almotriptan | | indoles;
sulfonamide;
tertiary amine | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ay 25545 | | acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| otonecine | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| di-allate | | tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzphetamine | | amphetamines;
tertiary amine | adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-(dimethylamino)styryl)-1-methylpyridinium | | organic iodide salt;
pyridinium salt;
tertiary amine | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-dihexadecylaminostyryl)-n-methylpyridium | | pyridinium ion;
tertiary amine | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fm1 43 | | organic bromide salt;
pyridinium salt;
quaternary ammonium salt;
tertiary amine | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceratamine a | | alkaloid;
aromatic ether;
cyclic ketone;
organic heterobicyclic compound;
organobromine compound;
secondary amino compound;
tertiary amine | antimitotic;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picogreen | | benzothiazoles;
cyanine dye;
quinolines;
tertiary amine | fluorescent dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sybr green i | | benzothiazolium ion;
cyanine dye;
quinolines;
tertiary amine | fluorescent dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dinitrochlorobenzene | | C-nitro compound;
monochlorobenzenes | allergen;
epitope;
sensitiser | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pk 11195 | | aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)biguanide | | biguanides;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorocresol | | hydroxytoluene;
monochlorobenzenes | antimicrobial agent;
disinfectant;
ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| win 53338 | | isoxazoles;
monochlorobenzenes | antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acemetacin | | carboxylic ester;
indol-3-yl carboxylic acid;
monocarboxylic acid;
monochlorobenzenes;
N-acylindole | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rtki cpd | | aromatic ether;
monochlorobenzenes;
quinazolines | antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azelastine | | monochlorobenzenes;
phthalazines;
tertiary amino compound | anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azosemide | | monochlorobenzenes;
sulfonamide;
tetrazoles;
thiophenes | loop diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbinoxamine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | | hydrazone;
monochlorobenzenes;
nitrile | antibacterial agent;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorhexidine | | biguanides;
monochlorobenzenes | antibacterial agent;
antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chloroxylenol | | monochlorobenzenes;
phenols | antiseptic drug;
disinfectant;
molluscicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorphenesin carbamate | | carbamate ester;
monochlorobenzenes;
secondary alcohol | muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| chlorpropamide | | monochlorobenzenes;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorpropham | | benzenes;
carbamate ester;
monochlorobenzenes | herbicide;
plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorthalidone | | isoindoles;
monochlorobenzenes;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clemizole | | benzimidazoles;
monochlorobenzenes;
pyrrolidines | histamine antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clorprenaline | | ethanolamines;
monochlorobenzenes;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| croconazole | | aromatic ether;
conazole antifungal drug;
imidazole antifungal drug;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlorodiphenyl dichloroethylene | | chlorophenylethylene;
monochlorobenzenes | human xenobiotic metabolite;
persistent organic pollutant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| econazole | | dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenvalerate | | aromatic ether;
carboxylic ester;
monochlorobenzenes | pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lofepramine | | aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound | antidepressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nemonapride | | benzamides;
monochlorobenzenes;
monomethoxybenzene;
N-alkylpyrrolidine;
secondary amino compound;
secondary carboxamide;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niclosamide | | benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide | anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ag 1879 | | aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine | beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| proglumetacin | | aromatic ether;
benzamides;
carboxylic ester;
monochlorobenzenes;
N-acylindole;
N-alkylpiperazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 1998 | 2022 | 13.5 | low | 13 | 0 | 2 | 19 | 15 | 1 |
| sulconazole | | dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zomepirac | | aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles | cardiovascular drug;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlorodiphenyldichloroethane | | chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| systhane | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buclizine | | monochlorobenzenes;
N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
histamine antagonist;
local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bis(p-chlorophenyl)acetic acid | | monocarboxylic acid;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-chloro-2-nitrobenzene | | C-nitro compound;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picryl chloride | | C-nitro compound;
monochlorobenzenes | allergen;
epitope;
explosive;
hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3'-dichlorobenzidine | | biphenyls;
monochlorobenzenes;
organochlorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mecoprop | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-4-chlorophenoxyacetic acid | | chlorophenoxyacetic acid;
monochlorobenzenes | environmental contaminant;
phenoxy herbicide;
synthetic auxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-4-chlorophenoxy gamma-butyric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | environmental contaminant;
phenoxy herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chloro-4-methylaniline | | chloroaniline;
monochlorobenzenes | avicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloro-1,2-diaminobenzene | | monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fentichlor | | aryl sulfide;
bridged diphenyl antifungal drug;
monochlorobenzenes;
polyphenol | antiinfective agent;
drug allergen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dyrene | | monochlorobenzenes;
organochlorine pesticide;
secondary amino compound;
triazines | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triclocarban | | dichlorobenzene;
monochlorobenzenes;
phenylureas | antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| barban | | acetylenic compound;
carbamate ester;
monochlorobenzenes | herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorphenesin | | glycol;
monochlorobenzenes;
propane-1,2-diols | antibacterial drug;
antifungal drug;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorotoluene | | monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloroaniline | | chloroaniline;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorobenzene | | monochlorobenzenes | solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicofol | | monochlorobenzenes;
organochlorine acaricide;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetradifon | | monochlorobenzenes;
organochlorine acaricide;
sulfone;
trichlorobenzene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chloroprocaine | | benzoate ester;
monochlorobenzenes | central nervous system depressant;
local anaesthetic;
peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monuron | | 3-(3,4-substituted-phenyl)-1,1-dimethylurea;
monochlorobenzenes | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-chlorosalicylic acid | | chlorobenzoic acid;
monochlorobenzenes;
monohydroxybenzoic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cloflucarban | | monochlorobenzenes;
phenylureas | antibacterial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloroacetanilide | | acetamides;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrrolnitrin | | alkaloid;
C-nitro compound;
monochlorobenzenes;
pyrroles | antifungal drug;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloro-2-cresol | | monochlorobenzenes;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorophenylacetic acid | | monocarboxylic acid;
monochlorobenzenes | xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,4'-dichlorobiphenyl | | dichlorobiphenyl;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorocatechol | | chlorocatechol;
monochlorobenzenes | bacterial xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-4-aminobenzoic acid | | aminobenzoic acid;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ddms | | chlorophenylethane;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-chlorophenol | | halophenol;
monochlorobenzenes;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chlorocatechol | | chlorocatechol;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorophenoxyacetic acid | | chlorophenoxyacetic acid;
monochlorobenzenes | phenoxy herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clemastine | | monochlorobenzenes;
N-alkylpyrrolidine | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlortoluron | | monochlorobenzenes;
phenylureas | agrochemical;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxuron | | 3-(3,4-substituted-phenyl)-1,1-dimethylurea;
monochlorobenzenes;
monomethoxybenzene | agrochemical;
environmental contaminant;
herbicide;
photosystem-II inhibitor;
plant growth regulator;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alclofenac | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benthiocarb | | monochlorobenzenes;
monothiocarbamic ester | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4'-dichlorobiphenyl | | dichlorobiphenyl;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflubenzuron | | benzoylurea insecticide;
monochlorobenzenes | insect sterilant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| climbazole | | aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| profenofos | | monochlorobenzenes;
organic thiophosphate;
organochlorine insecticide;
organophosphate insecticide | acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triadimefon | | aromatic ether;
hemiaminal ether;
ketone;
monochlorobenzenes;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes | antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triadimenol | | aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| closantel | | aromatic amide;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile;
organoiodine compound;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenarimol | | monochlorobenzenes;
pyrimidines;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triflumuron | | aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butoconazole | | aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorsulfuron | | methoxy-1,3,5-triazine;
monochlorobenzenes;
N-sulfonylurea | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvalinate | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fomesafen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3,4,4'5-pentachlorobiphenyl | | monochlorobenzenes;
pentachlorobiphenyl;
tetrachlorobenzene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clomazone | | isoxazolidinone;
monochlorobenzenes | agrochemical;
carotenoid biosynthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tepoxalin | | aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles | antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eliprodil | | monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazuron | | aromatic ether;
chloropyridine;
monochlorobenzenes;
N-acylurea;
organochlorine acaricide;
organofluorine acaricide;
phenylureas | acaricide;
mite growth regulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flucofuron | | (trifluoromethyl)benzenes;
monochlorobenzenes;
organochlorine pesticide;
organofluorine pesticide;
phenylureas | epitope | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonazolac | | monocarboxylic acid;
monochlorobenzenes;
pyrazoles | antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chloroperbenzoic acid | | monochlorobenzenes;
peroxy acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofentezine | | monochlorobenzenes;
organochlorine acaricide;
tetrazine | mite growth regulator;
tetrazine acaricide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tebuconazole | | monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyproconazole | | cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chlorophenyl)-2-phenyl-2-(1,2,4-triazol-1-ylmethyl)butanenitrile | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metconazole | | conazole fungicide;
cyclopentanols;
monochlorobenzenes;
tertiary alcohol;
triazole fungicide;
triazoles | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cloransulam-methyl | | methyl ester;
monochlorobenzenes;
organofluorine compound;
sulfonamide;
triazolopyrimidines | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-5-chlorophenol | | monochlorobenzenes;
phenols;
primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pencycuron | | monochlorobenzenes;
phenylureas | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazinam | | (trifluoromethyl)benzenes;
aminopyridine;
C-nitro compound;
chloropyridine;
monochlorobenzenes;
secondary amino compound | allergen;
antifungal agrochemical;
apoptosis inducer;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flufenoxuron | | (trifluoromethyl)benzenes;
benzoylurea insecticide;
difluorobenzene;
monochlorobenzenes;
monofluorobenzenes | mite growth regulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorfenapyr | | hemiaminal ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | proacaricide;
proinsecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclonifen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
primary amino compound;
substituted aniline | agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyraclofos | | monochlorobenzenes;
organic thiophosphate;
organochlorine insecticide;
organosulfur compound;
organothiophosphate insecticide;
pyrazoles | agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| novaluron | | aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chloro-L-tyrosine | | chloroamino acid;
L-alpha-amino acid zwitterion;
L-tyrosine derivative;
monochlorobenzenes;
non-proteinogenic L-alpha-amino acid | biomarker;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rh-0345 | | bisacylhydrazine insecticide;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chloro-4-hydroxyphenylacetic acid | | hydroxy monocarboxylic acid;
monochlorobenzenes;
phenols | mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mosapride | | aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vatalanib | | monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carpropamid | | amide fungicide;
cyclopropylcarboxamide;
monochlorobenzenes | antifungal agrochemical;
EC 4.2.1.94 (scytalone dehydratase) inhibitor;
melanin synthesis inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 23121 | | aromatic ether;
dicarboximide;
monochlorobenzenes;
monofluorobenzenes;
pyrroline;
terminal acetylenic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tipifarnib | | imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile | | monochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | acaricide;
antifouling biocide;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide | | anilide fungicide;
biphenyls;
monochlorobenzenes;
pyridinecarboxamide | antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabuzalgron | | aromatic ether;
imidazoles;
monochlorobenzenes;
sulfonamide | alpha-adrenergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 778,123 | | imidazoles;
monochlorobenzenes;
nitrile;
piperazinone;
tertiary amino compound | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea | | monochlorobenzenes;
phenylureas;
pyrazoles | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine | | 6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorocinnamic acid | | monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oncrasin-1 | | arenecarbaldehyde;
indoles;
monochlorobenzenes | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-1-(4-chlorophenyl)-2-oxo-4-(1,2,4-triazol-1-ylmethyl)-5-pyrimidinecarbonitrile | | monochlorobenzenes;
nitrile;
pyrimidone;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(4-chlorophenyl)methyl]-2-(2,4-dioxo-1H-pyrimidin-6-yl)acetamide | | monochlorobenzenes;
pyrimidone;
secondary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capsazepine | | benzazepine;
catechols;
monochlorobenzenes;
thioureas | capsaicin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-chlorophenyl)-3-[4-methyl-2-(thiophen-2-yl)-1,3-thiazol-5-yl]urea | | 1,3-thiazoles;
monochlorobenzenes;
phenylureas;
thiophenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(3-chloro-4-methylphenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide | | anilide fungicide;
monocarboxylic acid amide;
monochlorobenzenes;
organosulfur compound;
thiadiazoles | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate | | ethyl ester;
monochlorobenzenes;
organofluorine compound;
pyrazoles;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sr 144528 | | bridged compound;
monochlorobenzenes;
pyrazoles;
secondary carboxamide | CB2 receptor antagonist;
EC 2.3.1.26 (sterol O-acyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorobenzoyl coenzyme a | | chlorobenzoyl-CoA;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epoxiconazole | | epoxide;
monochlorobenzenes;
monofluorobenzenes;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 663536 | | aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes | antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 15572 | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol | geroprotector;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML162 | | monochlorobenzenes;
monomethoxybenzene;
organochlorine compound;
secondary carboxamide;
tertiary carboxamide;
thiophenes | EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-(2-chlorophenoxy)butyl]imidazole | | aromatic ether;
imidazoles;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clopidogrel carboxylic acid | | monocarboxylic acid;
monochlorobenzenes;
tertiary amino compound;
thienopyridine | drug metabolite;
marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 415286 | | C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline | antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 560 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ver-49009 | | aromatic amide;
monochlorobenzenes;
monomethoxybenzene;
pyrazoles;
resorcinols | Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jtk-303 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kn 93 | | monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound | EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(3-chlorostyryl)caffeine | | monochlorobenzenes;
trimethylxanthine | adenosine A2A receptor antagonist;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chlorochalcone | | chalcones;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethomorph | | aromatic ether;
enamide;
monochlorobenzenes;
morpholine fungicide;
tertiary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinidon-ethyl | | ethyl ester;
isoindoles;
monochlorobenzenes | herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2003 | 2011 | 17.9 | low | 3 | 0 | 0 | 10 | 1 | 0 |
| monorden | | cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols | antifungal agent;
metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clovoxamine | | 5-methoxyvalerophenone O-(2-aminoethyl)oxime;
monochlorobenzenes | antidepressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrachlostrobin | | aromatic ether;
carbamate ester;
carbanilate fungicide;
methoxycarbanilate strobilurin antifungal agent;
monochlorobenzenes;
pyrazoles | antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ascofuranone | | dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid;
tetrahydrofuranone | angiogenesis inhibitor;
antilipemic drug;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uniconazole | | monochlorobenzenes;
secondary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| strobilurin b | | enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
monochlorobenzenes;
monomethoxybenzene | antifungal agent;
fungal metabolite;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prothioconazole | | cyclopropanes;
monochlorobenzenes;
tertiary alcohol;
thiocarbonyl compound;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminopurvalanol a | | monochlorobenzenes;
purvalanol | protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorhexidine | | biguanides;
monochlorobenzenes | antibacterial agent;
antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-demethylloperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sd 0006 | | monochlorobenzenes;
N-acylpiperidine;
primary alcohol;
pyrazoles;
pyrimidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dapagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| solabegron | | carboxybiphenyl;
monochlorobenzenes;
secondary alcohol;
secondary amino compound;
substituted aniline | beta-adrenergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ki16425 | | carbamate ester;
isoxazoles;
monocarboxylic acid;
monochlorobenzenes;
organic sulfide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoxastrobin | | aromatic ether;
dioxazine;
monochlorobenzenes;
organofluorine compound;
oxime O-ether;
pyrimidines;
strobilurin antifungal agent | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7867 | | monochlorobenzenes;
piperidines;
pyrazoles | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erastin | | aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide | antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-737 | | aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound | anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzobicyclon | | aromatic ketone;
carbobicyclic compound;
cyclic ketone;
monochlorobenzenes;
organic sulfide;
sulfone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ascochlorin | | cyclohexanones;
dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid | angiogenesis inhibitor;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorantranilipole | | monochlorobenzenes;
organobromine compound;
pyrazole insecticide;
pyrazoles;
pyridines;
secondary carboxamide | ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mandipropamid | | aromatic ether;
monocarboxylic acid amide;
monochlorobenzenes;
terminal acetylenic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 8931 | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MI-63 | | azaspiro compound;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
oxindoles;
pyrrolidines;
secondary carboxamide | apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tembotrione | | aromatic ketone;
beta-triketone;
cyclic ketone;
ether;
monochlorobenzenes;
organofluorine compound;
sulfone | agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 0348292 | | monochlorobenzenes;
monofluorobenzenes;
pyridone;
pyrrolidines;
secondary carboxamide;
ureas | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butafenacil | | benzoate ester;
diester;
monochlorobenzenes;
olefinic compound;
organofluorine compound | EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| empagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methampicillin | | monochlorobenzenes;
tertiary alcohol;
triazoles | brassinosteroid biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine B | | aromatic amide;
aromatic ether;
isoxazoles;
monochlorobenzenes;
monofluorobenzenes;
N-acylpiperidine;
pyridines | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 7545 | | benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc 0449 | | benzamides;
monochlorobenzenes;
pyridines;
sulfone | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| navitoclax | | aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl]hydrazone | | 1,3-thiazoles;
hydrazone;
monochlorobenzenes | EC 2.3.1.48 (histone acetyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plx4032 | | aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ulixacaltamide | | benzamides;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary carboxamide | non-narcotic analgesic;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazaindolizine | | aromatic amide;
imidazopyridine;
monocarboxylic acid amide;
monochlorobenzenes;
monomethoxybenzene;
N-sulfonylcarboxamide;
organofluorine pesticide | agrochemical;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML-210 | | C-nitro compound;
diarylmethane;
isoxazoles;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
tertiary carboxamide | antineoplastic agent;
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 4800567 | | aromatic ether;
monochlorobenzenes;
oxanes;
pyrazolopyrimidine | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pelabresib | | monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide | antineoplastic agent;
bromodomain-containing protein 4 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MS-417 | | methyl ester;
monochlorobenzenes;
thienotriazolodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ivosidenib | | cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3h)-quinazolinone | | aryl phosphate;
monochlorobenzenes;
quinazolines | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| liproxstatin-1 | | azaspiro compound;
monochlorobenzenes;
organic heterotricyclic compound;
secondary amino compound | antioxidant;
cardioprotective agent;
ferroptosis inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monoisopropanolamine | | amino alcohol;
secondary alcohol | Escherichia coli metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-butylene glycol | | butanediol;
glycol;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isocitric acid | | secondary alcohol;
tricarboxylic acid | fundamental metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| menthol | | p-menthane monoterpenoid;
secondary alcohol | volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alprenolol | | secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carteolol | | quinolone;
secondary alcohol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgp 12177 | | aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound | beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclandelate | | carboxylic ester;
secondary alcohol | vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol | | benzyl alcohols;
fatty amide;
morpholines;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| formoterol fumarate | | formamides;
phenols;
phenylethanolamines;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metaproterenol | | aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methocarbamol | | aromatic ether;
carbamate ester;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| practolol | | acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salmeterol xinafoate | | ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sotalol | | ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide | anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-butanol | | secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pseudoephedrine | | phenylethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzohydrol | | benzyl alcohols;
secondary alcohol | bacterial xenobiotic metabolite;
human urinary metabolite;
human xenobiotic metabolite;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dichloro-2-propanol | | organochlorine compound;
secondary alcohol | cross-linking reagent;
protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl lactate | | ethyl ester;
lactate ester;
secondary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 12-hydroxy stearic acid | | hydroxyoctadecanoic acid;
secondary alcohol | bacterial xenobiotic metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclohexanol | | cyclohexanols;
secondary alcohol | solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diisopropanolamine | | aminodiol;
secondary alcohol;
secondary amino compound | buffer;
emulsifier;
surfactant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3,5-trimethylcyclohexanol | | cyclohexanols;
secondary alcohol | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-5-(1-methylethenyl)cyclohexanol | | p-menthane monoterpenoid;
secondary alcohol | acaricide;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hexanol | | hexanol;
secondary alcohol | human metabolite;
plant metabolite;
semiochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-nonanol | | nonanol;
secondary alcohol | bacterial metabolite;
flavouring agent;
pheromone;
plant metabolite;
rat metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl mandelate | | ethyl ester;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexafluoroisopropanol | | organofluorine compound;
secondary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-undecanol | | secondary alcohol;
undecanol | animal metabolite;
flavouring agent;
pheromone;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spectinomycin | | cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,5-hexanediol | | glycol;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-octanol | | octanol;
secondary alcohol | plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulcatol | | secondary alcohol | pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-indanol | | aromatic alcohol;
indanes;
secondary alcohol | xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| helenalin | | cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
secondary alcohol;
sesquiterpene lactone | anti-inflammatory agent;
antineoplastic agent;
metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| colterol | | catechols;
ethanolamines;
secondary alcohol;
secondary amino compound;
triol | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ornidazole | | C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol | antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-chloro-2-propanol | | organochlorine compound;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| du-21220 | | benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bitolterol | | carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diisopropanolnitrosamine | | diol;
nitrosamine;
secondary alcohol | carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| st 1059 | | aromatic ether;
primary amino compound;
secondary alcohol | alpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ractopamine | | benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ranolazine | | aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lisofylline | | dimethylxanthine;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| esmolol | | aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| calanolide a | | cyclic ether;
delta-lactone;
organic heterotetracyclic compound;
secondary alcohol | HIV-1 reverse transcriptase inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cephalotaxine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 16-hydroxytestosterone | | 16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid;
C19-steroid;
diol;
secondary alcohol | androgen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nebivolol | | chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| secnidazole | | C-nitro compound;
imidazoles;
secondary alcohol | epitope | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zaluzanin C | | gamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
secondary alcohol;
sesquiterpene lactone | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-amyrin | | pentacyclic triterpenoid;
secondary alcohol | Aspergillus metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-amyrin | | pentacyclic triterpenoid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mandelamide | | benzyl alcohols;
monocarboxylic acid amide;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoren-9-ol | | hydroxyfluorenes;
secondary alcohol | animal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loganin | | beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol | anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyano-2-hydroxy-3-butene | | secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bitertanol | | aromatic ether;
biphenyls;
secondary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taraxerol | | pentacyclic triterpenoid;
secondary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,4'-oxydi-2-butanol | | secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lactamide | | monocarboxylic acid amide;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sporidesmin | | aromatic ether;
cyclic ketone;
diketone;
organic disulfide;
organic heteropentacyclic compound;
organochlorine compound;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | mycotoxin;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erythrodiol | | diol;
pentacyclic triterpenoid;
primary alcohol;
secondary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,6-dimethyl-2-methylenebicyclo(3.1.1)heptan-3-ol | | carbobicyclic compound;
pinane monoterpenoid;
secondary alcohol | GABA modulator;
mouse metabolite;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol | | nitrosamine;
pyridines;
secondary alcohol | biomarker;
carcinogenic agent;
human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxydebrisoquin | | carboxamidine;
isoquinolines;
secondary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tabtoxin | | dipeptide;
L-threonine derivative;
monobactam;
secondary alcohol | bacterial metabolite;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| florfenicol | | organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone | antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| megestrol acetate | | bridged compound;
organic heterotetracyclic compound;
secondary alcohol;
sesquiterpene lactone;
spiro compound;
tertiary alcohol;
tetrol | GABA antagonist;
neurotoxin;
phytogenic insecticide;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taraxasterol | | pentacyclic triterpenoid;
secondary alcohol | anti-inflammatory agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cubebin | | benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol | analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bw 245c | | imidazolidine-2,4-dione;
monocarboxylic acid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| conduritol b | | cyclitol;
secondary alcohol;
tetrol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| withanolide d | | 20-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
tertiary alcohol;
withanolide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ml 236a | | 2-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol | antiatherosclerotic agent;
anticholesteremic drug;
antilipemic drug;
antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| corynoline | | benzophenanthridine alkaloid;
cyclic acetal;
isoquinolines;
organic heterohexacyclic compound;
secondary alcohol | antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fumagillol | | secondary alcohol;
sesquiterpenoid;
spiro-epoxide | antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lupeol | | pentacyclic triterpenoid;
secondary alcohol | anti-inflammatory drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| withaferin a | | 27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxypropylphosphonic acid | | phosphonic acids;
secondary alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xv 638 | | 1,3-thiazoles;
benzamides;
diazepanone;
diol;
secondary alcohol;
secondary carboxamide;
ureas | HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hippeastrine | | delta-lactone;
indole alkaloid;
organic heteropentacyclic compound;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decursinol | | cyclic ether;
delta-lactone;
organic heterotricyclic compound;
secondary alcohol | analgesic;
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lactucin | | azulenofuran;
cyclic terpene ketone;
enone;
primary alcohol;
secondary alcohol;
sesquiterpene lactone | antimalarial;
plant metabolite;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yersiniabactin | | monocarboxylic acid;
phenols;
secondary alcohol;
thiazolidines | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prostaglandin h2 | | olefinic compound;
oxylipin;
prostaglandins H;
secondary alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (north)-methanocarbathymidine | | C-glycosyl pyrimidine;
carbobicyclic compound;
primary alcohol;
pyrimidone;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mupirocin | | alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol | antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| costatolide | | cyclic ether;
delta-lactone;
organic heterotetracyclic compound;
secondary alcohol | HIV-1 reverse transcriptase inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 1163a | | aromatic ether;
lactam;
macrolide antibiotic;
secondary alcohol | antifungal agent;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiamulin | | carbotricyclic compound;
carboxylic ester;
cyclic ketone;
organic sulfide;
secondary alcohol;
semisynthetic derivative;
tertiary amino compound;
tetracyclic diterpenoid | antibacterial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wiskostatin | | carbazoles;
organobromine compound;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| galanal a | | secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| australifungin | | carbobicyclic compound;
enol;
enone;
secondary alcohol | antifungal agent;
EC 2.3.1.24 (sphingosine N-acyltransferase) inhibitor;
HIV-1 integrase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bryostatin 1 | | acetate ester;
bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol | alpha-secretase activator;
anti-HIV-1 agent;
antineoplastic agent;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leukotriene e4 | | amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | | prostaglandins J;
secondary alcohol | antineoplastic agent;
antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| previtamin d(3) | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azadirachtin | | acetate ester;
azadirachtin;
cyclic hemiketal;
enoate ester;
epoxide;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol;
tertiary alcohol | hepatoprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| strigol | | indenofuran;
secondary alcohol;
strigolactone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eupatolide | | gamma-lactone;
germacranolide;
homoallylic alcohol;
secondary alcohol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 683590 | | ether;
lactol;
macrolide;
secondary alcohol | antifungal agent;
bacterial metabolite;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 17-phenyltrinorprostaglandin e2 | | alicyclic ketone;
beta-hydroxy ketone;
hydroxy monocarboxylic acid;
olefinic compound;
oxo monocarboxylic acid;
prostanoid;
secondary alcohol | human metabolite;
prostaglandin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dinor-6-ketoprostaglandin f1alpha | | 4-oxo monocarboxylic acid;
prostanoid;
secondary alcohol | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-isoprostaglandin e2 | | cyclic ketone;
diol;
prostanoid;
secondary alcohol | bronchoconstrictor agent;
human metabolite;
rat metabolite;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| calcipotriene | | cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol | antipsoriatic;
drug allergen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay u9773 | | benzoic acids;
dicarboxylic acid;
organic sulfide;
polyunsaturated fatty acid;
secondary alcohol | leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| andrographolide | | carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol | anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oridonin | | cyclic hemiketal;
enone;
ent-kaurane diterpenoid;
organic heteropentacyclic compound;
secondary alcohol | angiogenesis inhibitor;
anti-asthmatic agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasalocid | | beta-hydroxy ketone;
monocarboxylic acid;
monohydroxybenzoic acid;
oxanes;
oxolanes;
polyether antibiotic;
secondary alcohol;
tertiary alcohol | bacterial metabolite;
coccidiostat;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pederin | | cyclic ketal;
diol;
oxanes;
polyketide;
secondary alcohol;
secondary carboxamide | antimitotic;
antineoplastic agent;
bacterial metabolite;
vesicant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| streptogramin a | | 1,3-oxazoles;
cyclic ketone;
enamide;
lactam;
macrolide antibiotic;
macrolide;
pyrroline;
secondary alcohol;
secondary carboxamide;
tertiary carboxamide | antibacterial drug;
Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benanomicin b | | aromatic ether;
disaccharide derivative;
L-alanine derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pradimicin b | | aromatic ether;
L-alanine derivative;
monosaccharide derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| poricoic acid a | | dicarboxylic acid;
secondary alcohol;
tricyclic triterpenoid | fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| poricoic acid g | | dicarboxylic acid;
secondary alcohol;
tricyclic triterpenoid | fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pradimicin a | | aromatic ether;
carboxylic acid;
disaccharide derivative;
L-alanine derivative;
p-quinones;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 685458 | | carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ici 118551 | | aromatic ether;
indanes;
secondary alcohol;
secondary amino compound | beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diniconazole | | dichlorobenzene;
olefinic compound;
secondary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bryostatin 2 | | bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol | antineoplastic agent;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terpestacin | | secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chaetoviridin a | | azaphilone;
beta-hydroxy ketone;
enone;
gamma-lactone;
organic heterotricyclic compound;
organochlorine compound;
secondary alcohol | antifungal agent;
Chaetomium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 25-6981 | | benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound | anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yunaconitine | | acetate ester;
aromatic ether;
benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | antifeedant;
human urinary metabolite;
phytotoxin;
plant metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| laulimalide | | carboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol | animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indacaterol | | indanes;
monohydroxyquinoline;
quinolone;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| grayanotoxin i | | acetate ester;
pentol;
secondary alcohol;
tertiary alcohol;
tetracyclic diterpenoid | antihypertensive agent;
metabolite;
neuromuscular agent;
phytotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 148083 | | aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95a | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monacolin j | | 2-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol | antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ustiloxin b | | aromatic ether;
heterodetic cyclic peptide;
macrocycle;
phenols;
secondary alcohol;
secondary carboxamide;
sulfoxide | Aspergillus metabolite;
microtubule-destabilising agent;
mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glutinol | | pentacyclic triterpenoid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-epi-fagomine | | amino monosaccharide;
hydroxypiperidine;
primary alcohol;
secondary alcohol;
secondary amino compound;
triol | EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor;
EC 3.2.1.23 (beta-galactosidase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 411575 | | dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manassantin b | | benzodioxoles;
dimethoxybenzene;
lignan;
oxolanes;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95b | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ossamycin | | cyclic hemiketal;
macrolide antibiotic;
organic heterotetracyclic compound;
secondary alcohol;
spiroketal;
tertiary alcohol | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dihydro-3beta-methoxy withaferin A | | 27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide | metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| migrastatin | | ether;
macrolide antibiotic;
piperidones;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allobetulinol | | cyclic ether;
secondary alcohol;
triterpenoid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brivanib | | aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-onocerin | | diol;
olefinic compound;
secondary alcohol;
triterpenoid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| olodaterol | | aromatic ether;
benzoxazine;
phenols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cortistatin a | | cortistatins;
diol;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amrubicinol | | diastereoisomeric mixture;
quinone;
secondary alcohol;
tetracenes | antineoplastic agent;
apoptosis inducer;
topoisomerase II inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytotrienin a | | cyclopropanecarboxylate ester;
ether;
hydroquinones;
lactam;
macrocycle;
secondary alcohol | antibacterial agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrostatin a | | 1,4,5,6-tetrahydropyrimidines;
carboxamidine;
iminium betaine;
monocarboxylic acid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oplodiol | | carbobicyclic compound;
octahydronaphthalenes;
secondary alcohol;
sesquiterpenoid;
tertiary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| simalikalactone D | | cyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
triol | antimalarial;
antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monacolin l | | 2-pyranones;
hexahydronaphthalenes;
polyketide;
secondary alcohol | anticholesteremic drug;
Aspergillus metabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dihydrowithaferin A | | 27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adonixanthin | | carotenone;
cyclic ketone;
secondary alcohol | algal metabolite;
animal metabolite;
antineoplastic agent;
bacterial metabolite;
marine metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3'-hydroxyechinenone | | carotenone;
enone;
secondary alcohol | bacterial metabolite;
biological pigment;
cofactor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tubocapsanolide a | | 4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
withanolide | antineoplastic agent;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyranonigrin a | | cyclic ketone;
enol;
gamma-lactam;
pyranopyrrole;
secondary alcohol | antioxidant;
Aspergillus metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tricin 4'-o-(threo-beta-guaiacylglyceryl) ether | | dimethoxybenzene;
flavonolignan;
polyphenol;
primary alcohol;
secondary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucidenic acid n | | cyclic terpene ketone;
dioxo monocarboxylic acid;
secondary alcohol;
tetracyclic triterpenoid | antineoplastic agent;
EC 3.1.1.8 (cholinesterase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deoxyaconitine | | acetate ester;
benzoate ester;
bridged compound;
diol;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary amino compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4'-epichaetoviridin A | | azaphilone;
beta-hydroxy ketone;
enone;
gamma-lactone;
organic heterotricyclic compound;
organochlorine compound;
secondary alcohol | Chaetomium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eliglustat | | benzodioxine;
carboxamide;
N-alkylpyrrolidine;
secondary alcohol | EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| borrelidin | | aliphatic nitrile;
diol;
macrolide;
monocarboxylic acid;
secondary alcohol | antifungal agent;
antimalarial;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide b | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delanzomib | | C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative | antineoplastic agent;
apoptosis inducer;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylmesaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | analgesic;
antiinfective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| papuamide b | | cyclodepsipeptide;
olefinic compound;
secondary alcohol;
tertiary alcohol | anti-HIV-1 agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| albiflorin | | benzoate ester;
beta-D-glucoside;
bridged compound;
gamma-lactone;
monoterpene glycoside;
secondary alcohol | neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| antroquinonol d | | enol ether;
enone;
secondary alcohol | antineoplastic agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bacillaene | | enamine;
monocarboxylic acid amide;
polyene antibiotic;
polyketide;
secondary alcohol | antibacterial agent;
antimicrobial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fumonisin b4 | | diester;
fumonisin;
primary amino compound;
secondary alcohol | Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cay 10580 | | hydroxy monocarboxylic acid;
pyrrolidin-2-ones;
secondary alcohol | prostaglandin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| debromoaplysiatoxin | | aplysiatoxins;
cyclic hemiketal;
ether;
organic heterotricyclic compound;
phenols;
secondary alcohol;
spiroketal | algal metabolite;
carcinogenic agent;
cyanotoxin;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aplysiatoxin | | aplysiatoxins;
bromophenol;
cyclic hemiketal;
ether;
organic heterotricyclic compound;
secondary alcohol;
spiroketal | algal metabolite;
carcinogenic agent;
cyanotoxin;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eurycomanone | | cyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
pentol;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
tertiary alcohol | antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crambescidin 800 | | alkaloid;
carboxylic ester;
guanidines;
monocarboxylic acid amide;
organic heteropentacyclic compound;
primary amino compound;
secondary alcohol;
spiro compound | anti-HIV-1 agent;
anti-HSV-1 agent;
antimalarial;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| afidopyropen | | cyclopropanecarboxylate ester;
organic heterotetracyclic compound;
pyridines;
secondary alcohol | agrochemical;
insecticide;
TRPV channel modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| orobanchol | | indenofuran;
secondary alcohol;
strigolactone | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asperfuranone | | 2-benzofurans;
cyclic ketone;
diol;
polyketide;
secondary alcohol;
tertiary alcohol;
tertiary alpha-hydroxy ketone | antineoplastic agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide a | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capilliposide b | | alpha-L-arabinopyranoside;
bridged compound;
cyclic ether;
diol;
hexacyclic triterpenoid;
hexanoate ester;
lactol;
secondary alcohol;
tetrasaccharide derivative;
triterpenoid saponin | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myriaporone 3 | | beta-hydroxy ketone;
epoxide;
lactol;
oxanes;
primary alcohol;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| BDA-366 | | anthraquinone;
epoxide;
secondary alcohol;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclooctatin | | carbotricyclic compound;
diterpenoid;
primary alcohol;
secondary alcohol;
tertiary alcohol | bacterial metabolite;
EC 3.1.1.5 (lysophospholipase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entecavir | | 2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysogine | | cyclic amide;
quinazoline alkaloid;
quinazolines;
secondary alcohol;
secondary amide | Aspergillus metabolite;
biological pigment;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-fluorenylacetamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-acetylaminofluorene | | acetamides;
fluorenes | mitogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indecainide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxyfluorene | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9,9-bis(4-hydroxyphenyl)fluorene | | fluorenes;
polyphenol | anti-estrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-methoxyphenyl)carbamic acid (9-fluorenylideneamino) ester | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(dimethylsulfamoylamino)-9H-fluorene | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-oxo-3-fluorenecarboxylic acid (phenylmethyl) ester | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-{[(9H-9-fluorenylmethoxy)carbonyl]amino}benzoic acid | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N2,N7-bis(2,5-dimethylphenyl)-9H-fluorene-2,7-disulfonamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-(3-aminophenyl)-4-methyl-1,2,4-triazol-3-yl]thio]-1-(9H-fluoren-2-yl)ethanone | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(4-ethoxyphenyl)-oxomethyl]amino]acetic acid [2-(9H-fluoren-3-yl)-2-oxoethyl] ester | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-bromo-N-(9-fluorenylideneamino)benzamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-butoxy-7-hydroxy-9-fluorenone | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(9H-fluoren-9-yl)-N-phenyl-1-piperazinecarboxamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-chlorophenyl)-4-(9H-fluoren-9-yl)-1-piperazinecarboxamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-hydroxyiminofluorene-2,7-disulfonamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(9H-fluoren-9-yl)-1-piperazinyl]-N-(4-methoxyphenyl)acetamide | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms201038 | | (trifluoromethyl)benzenes;
benzamides;
fluorenes;
piperidines | anticholesteremic drug;
MTP inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ngb 2904 | | fluorenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ledipasvir | | azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound | antiviral drug;
hepatitis C protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2019 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 3-(1-methylpyrrolidin-2-yl)pyridine | | N-alkylpyrrolidine;
pyridine alkaloid;
pyrrolidine alkaloid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | | non-proteinogenic alpha-amino acid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate | | catechin | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,3-dipropyl-8-cyclopentylxanthine | | oxopurine | adenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nsc-267703 | | anthracycline | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-aminopyridine | | aminopyridine;
aromatic amine | avicide;
orphan drug;
potassium channel blocker | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dactinomycin | | cyclodepsipeptide | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-aminoindan-1,5-dicarboxylic acid | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amodiaquine | | aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 2011 | 2020 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | | aporphine alkaloid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2004 | 2011 | 15.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| bepridil | | pyrrolidines;
tertiary amine | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| berberine | | alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound | antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bisindolylmaleimide i | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 2004 | 2011 | 16.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2002 | 2020 | 13.9 | low | 1 | 0 | 0 | 13 | 9 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cifenline | | diarylmethane | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aricine | | cinchona alkaloid | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cisapride | | benzamides | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clebopride | | piperidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clofilium | | benzenes;
organic amino compound | | 2004 | 2011 | 15.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2008 | 2011 | 14.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cocaine | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dequalinium | | quinolinium ion | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dilacor xr | | acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| e 4031 | | sulfonamide | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ebastine | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nsc-526417 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluspirilene | | diarylmethane | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gentian violet | | iminium ion | antibacterial agent;
antifungal agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| granisetron | | aromatic amide;
indazoles | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hexahydrosiladifenidol | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ifenprodil | | piperidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lidoflazine | | diarylmethane | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lomefloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| loratadine | | benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide | anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 2004 | 2011 | 15.4 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| meperidine | | ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound | antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mesoridazine | | phenothiazines;
sulfoxide;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2011 | 14.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| n-acetyl-4-nitrophenylserinol | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| acecainide | | acetamides;
benzamides | anti-arrhythmia drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nifekalant | | amine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| norfluoxetine | | (trifluoromethyl)benzenes | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ondansetron | | carbazoles | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxiracetam | | organonitrogen compound;
organooxygen compound | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| papaverine | | benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines | antispasmodic drug;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pentobarbital | | barbiturates | GABAA receptor agonist | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| perhexiline | | piperidines | cardiovascular drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pilsicainide | | organic heterobicyclic compound;
secondary carboxamide | anti-arrhythmia drug;
sodium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 2009 | 2020 | 7.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procainamide | | benzamides | anti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pronethalol | | naphthalenes | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 2004 | 2011 | 16.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pyrilamine | | aromatic ether;
ethylenediamine derivative | H1-receptor antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2002 | 2020 | 16.0 | low | 0 | 0 | 0 | 7 | 3 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| scriptaid | | isoquinolines | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terfenadine | | diarylmethane | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone | | cyclodepsipeptide | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| vesnarinone | | organic molecular entity | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlorobutanol | | tertiary alcohol | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phanquinone | | orthoquinones | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| brompheniramine | | organobromine compound;
pyridines | anti-allergic agent;
H1-receptor antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diphenan | | diarylmethane | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-phenylacetamide | | monocarboxylic acid amide | mouse metabolite | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| tetraphenylborate | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cycloguanil hydrochloride | | hydrochloride;
organic molecular entity | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| cycloguanil | | triazines | antifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2002 | 2013 | 17.9 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| benzo(c)cinnoline | | | | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| triphenyltetrazolium | | organic cation | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| berbamine | | phenylpropanoid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dequalinium chloride | | organic chloride salt | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Berberine chloride (TN) | | organic molecular entity | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| erythromycin | | cyclic ketone;
erythromycin | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 9,10-dimethylanthracene | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| c 137 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfadoxine | | pyrimidines;
sulfonamide | antibacterial drug;
antimalarial | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| palmatine | | berberine alkaloid;
organic heterotetracyclic compound | plant metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| buquinolate | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| terodiline | | diarylmethane | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| edifenphos | | organic thiophosphate | antifungal agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neurotoxin;
phospholipid biosynthesis inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| decoquinate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propranolol glycol | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| halofantrine | | phenanthrenes | | 2004 | 2017 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2012 | 2019 | 8.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| naphthoxybutanolcyclohexylamine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| staurosporine | | indolocarbazole alkaloid;
organic heterooctacyclic compound | apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicifadine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ibutilide | | benzenes;
organic amino compound | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chloroquine diphosphate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propamidine | | aromatic ether;
guanidines;
polyether | antimicrobial agent;
antiseptic drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thionine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| neocuproine | | phenanthrolines | chelator;
copper chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mefloquine hydrochloride | | hydrochloride | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mizolastine | | benzimidazoles | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terikalant | | piperidines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| toxoflavin | | carbonyl compound;
pyrimidotriazine | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| selfotel | | non-proteinogenic alpha-amino acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| budipine | | diarylmethane | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| artemisinin | | organic peroxide;
sesquiterpene lactone | antimalarial;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| plasmenylserine | | O-phosphoserine | EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| artemether | | artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid | antimalarial | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinocide | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2,2',2''-terpyridine | | terpyridines | chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clobetasone butyrate | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cletoquine | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| jatrorrhizine | | alkaloid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lycorine | | indolizidine alkaloid | anticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| grepafloxacin | | fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bathophenanthroline | | benzenes;
phenanthrolines | chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fascaplysine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| LSM-4272 | | beta-carbolines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dauricine | | aromatic ether;
bisbenzylisoquinoline alkaloid;
isoquinolines;
phenols;
tertiary amino compound | plant metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tryptanthrine | | alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2008 | 2020 | 8.5 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylhydrocupreine | | aromatic ether;
cinchona alkaloid | EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cinchonine | | (8xi)-cinchonan-9-ol;
cinchona alkaloid | metabolite | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinine hydrochloride | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| levobupivacaine | | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 7-chloro-4-aminoquinoline | | aminoquinoline | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mmv665852 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 1,3,4,10-Tetrahydro-9(2H)-acridinone | | acridines | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| wr 158122 | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 10-deazaaminopterin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ecgonine methyl ester | | methyl ester;
tertiary amino compound;
tropane alkaloid | analgesic;
central nervous system depressant;
metabolite;
mouse metabolite;
opioid analgesic;
peripheral nervous system drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydroergocristine | | ergot alkaloid | adrenergic antagonist;
vasodilator agent | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 5-hydroxypropafenone | | phenols | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzamil | | guanidines;
pyrazines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3',4'-dichlorobenzamil | | guanidines;
pyrazines | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cleistanthin b | | beta-D-glucoside;
cleistanthins;
monosaccharide derivative | alpha-adrenergic antagonist;
antihypertensive agent;
diuretic | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| mosapride | | aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-acetyltyramine | | acetamides;
tyramines | animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| desethylamodiaquine | | | | 2008 | 2010 | 15.0 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| piperaquine | | aminoquinoline;
N-arylpiperazine;
organochlorine compound | antimalarial | 2008 | 2020 | 11.3 | low | 1 | 0 | 0 | 6 | 4 | 0 |
| 1,3-di(4-imidazolinophenoxyl)propane | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-depropylpropafenone | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 7h-pyrido(4,3-c)carbazole | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| imiloxan | | benzodioxine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cl 246738 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mdl 74156 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| celastrol methyl ester | | carboxylic ester | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| epiberberine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-phenyl-4-oxohydroquinoline | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cypripedin | | phenanthrol | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| ly 97241 | | | | 2004 | 2011 | 16.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| emd 60263 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| respinomycin d | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| azacrin | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acetoxycycloheximide | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| (R)-Roemerine | | isoquinoline alkaloid | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| anisomycin | | monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-guanidine-4-methylquinazoline | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| jatrorrhizine chloride | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| mensacarcin | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cephaelin | | pyridoisoquinoline | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trichostatin a | | antibiotic antifungal agent;
hydroxamic acid;
trichostatin | bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| genz10850 | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| epothilone b | | epothilone;
epoxide | antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| wr-142,490 | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artenimol | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dactinomycin | | actinomycin | mutagen | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione | | pyrimidotriazine | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| jp-1302 | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| artemisin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 7-hydroxy-2-methoxy-1,4-phenanthrenedione | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| cgp 60474 | | substituted aniline | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide | | naphthols | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine | | aralkylamine | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| n-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 2,6-bis(benzimidazol-2-yl)pyridine | | benzimidazoles | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| N-[4-(1-azepanyl)phenyl]-2-chloroacetamide | | anilide | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester | | toluenes | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| (2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) | | benzimidazoles | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine | | aminoquinoline | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone | | aromatic amide;
heteroarene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone | | quinolines | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| stk295900 | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole | | benzimidazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| zuclomiphene | | stilbenoid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine | | aromatic ether | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline | | benzimidazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(1-adamantyl)-2-methyl-1,3-thiazole | | thiazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile | | piperazines;
pyridines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea | | pyrazoles;
ring assembly | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine | | quinazolines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| polysulfide rubber | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| lch-7749944 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide | | piperazines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| almokalant | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinine | | cinchona alkaloid | antimalarial;
muscle relaxant;
non-narcotic analgesic | 2002 | 2020 | 13.8 | low | 1 | 0 | 0 | 6 | 2 | 0 |
| glyceryl nonivamide | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| zd 6474 | | aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine | antineoplastic agent;
tyrosine kinase inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| benzyltetrahydropalmatine | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide | | indoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide | | aromatic amide;
heteroarene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| trichomonacid | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine | | triazolopyrimidines | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide | | isoindoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| l 365260 | | benzodiazepine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cgp 71683 a | | naphthalenes;
sulfonic acid derivative | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-(dimethylaminostyryl)-1-ethylpyridinium | | pyridinium ion | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| penicillin v | | 1,1'-diethyl-2,2'-cyanine;
quinolines | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate, (11beta)-isomer | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| xib 4035 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one | | pyridochromene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| suloctidil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 2008 | 2020 | 11.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| edatrexate | | glutamic acid derivative | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| azimilide | | imidazolidine-2,4-dione | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlorproguanil | | dichlorobenzene | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ave 0118 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cgp 71683 a | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hmr 1556 | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norketotifen | | organosulfur heterocyclic compound | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide | | piperazines;
pyridines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2,7-dibromocryptolepine | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artenimol | | | | 2008 | 2013 | 14.3 | low | 1 | 0 | 0 | 6 | 1 | 0 |
| aee 788 | | 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cj 033466 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| arterolane | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| marizomib | | beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide | antineoplastic agent;
proteasome inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| artemisone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tomaymycin | | tomaymycin | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cladosporin | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amodiaquine hydrochloride | | | | 2008 | 2013 | 14.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| gramicidin a | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide | | benzenes | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| du1301 | | | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rs 39604 | | hydrochloride | serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oz 439 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bix 01294 | | piperidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitd 609 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rka 182 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sildenafil | | piperazines;
pyrazolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea | | quinazolines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| norclozapine | | dibenzodiazepine;
organochlorine compound;
piperazines | delta-opioid receptor agonist;
metabolite;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desmethylolanzapine | | benzodiazepine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives.Bioorganic & medicinal chemistry, , Nov-01, Volume: 22, Issue:21, 2014
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.Bioorganic & medicinal chemistry, , Dec-15, Volume: 19, Issue:24, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:8, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:12, 2009
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:3, 2008
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 13, Issue:13, 2003
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , May-05, Volume: 13, Issue:9, 2003
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , Feb-10, Volume: 13, Issue:3, 2003
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:3, 2008
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 13, Issue:13, 2003
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , May-05, Volume: 13, Issue:9, 2003
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , Feb-10, Volume: 13, Issue:3, 2003
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 13, Issue:13, 2003
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , May-05, Volume: 13, Issue:9, 2003
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.Bioorganic & medicinal chemistry letters, , Feb-10, Volume: 13, Issue:3, 2003
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:8, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:12, 2009
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:3, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:8, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 13, Issue:13, 2003
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1, 2010
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:3, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:8, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:12, 2009
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:6, 2009
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1, 2010
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:7, 2009
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:3, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acute Coronary Syndrome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Disease | 0 | | 1998 | 2016 | 17.2 | low | 4 | 0 | 1 | 3 | 1 | 0 |
| Acute Kidney Failure | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Acute Kidney Injury | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Acute Respiratory Distress Syndrome | 0 | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Adverse Drug Event | 0 | | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| African Sleeping Sickness | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anemia | 0 | | 2006 | 2017 | 11.0 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Anemia, Hemolytic | 0 | | 2018 | 2021 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Anemia, Hemolytic, Acquired | 0 | | 2018 | 2021 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Anemia, Sickle Cell | 0 | | 2014 | 2022 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Arthritis, Rheumatoid | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Astrocytoma, Grade IV | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Asymptomatic Colonization | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Babesia Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Neoplasms, Brain | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilateral Headache | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Black Water Fever | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Poisoning | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Body Weight | 0 | | 2006 | 2020 | 11.7 | low | 3 | 0 | 0 | 3 | 4 | 0 |
| Brain Neoplasms | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Lung | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cerebral Malaria | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Circulatory Collapse | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Co-infection | 0 | | 2011 | 2018 | 8.8 | low | 0 | 0 | 0 | 0 | 6 | 0 |
| Cochlear Hearing Loss | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Complications, Infectious Pregnancy | 0 | | 2006 | 2012 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Complications, Parasitic Pregnancy | 0 | | 2005 | 2017 | 12.8 | low | 2 | 0 | 0 | 2 | 3 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cross Infection | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deafness, Transitory | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Disease Models, Animal | 0 | | 2009 | 2023 | 6.7 | low | 0 | 0 | 0 | 1 | 10 | 2 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Ebola Hemorrhagic Fever | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Electrocardiogram QT Prolonged | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Emesis | 0 | | 2004 | 2010 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Encephalopathy, Toxic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Enlarged Spleen | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Erythrophagocytic Lymphohistiocytosis, Familial | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Extravascular Hemolysis | 0 | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Fever | 1 | | 2006 | 2015 | 14.0 | low | 2 | 0 | 0 | 4 | 4 | 0 |
| Fever of Unknown Origin | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Gastric Ulcer | 0 | | 2018 | 2020 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Glioblastoma | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HbS Disease | 0 | | 2014 | 2022 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Headache | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Health Care Associated Infection | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hearing Loss | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Hearing Loss, Sensorineural | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Hemolysis | 0 | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Hemorrhagic Fever, Ebola | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HIV | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| HIV Coinfection | 0 | | 2006 | 2023 | 7.7 | low | 4 | 0 | 0 | 1 | 12 | 2 |
| HIV Infections | 1 | | 2006 | 2023 | 7.7 | low | 4 | 0 | 0 | 1 | 12 | 2 |
| Hyponatremia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infection Reactivation | 0 | | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 2 |
| Infection, Toxoplasma gondii | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Infections, Plasmodium | 0 | | 1998 | 2023 | 10.2 | medium | 18 | 0 | 2 | 31 | 62 | 16 |
| Inflammation | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Innate Inflammatory Response | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Insect Bites | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Insect Bites and Stings | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Koch's Disease | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lassa Fever | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lassa Virus Infection | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Long QT Syndrome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lung Neoplasms | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Lymphohistiocytosis, Hemophagocytic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Malaria | 1 | | 1998 | 2023 | 10.2 | medium | 18 | 0 | 2 | 31 | 62 | 16 |
| Malaria, Falciparum | 1 | | 1997 | 2023 | 12.2 | high | 91 | 0 | 13 | 89 | 107 | 24 |
| Malaria, Vivax | 1 | | 1999 | 2016 | 14.1 | low | 6 | 0 | 1 | 5 | 7 | 0 |
| Parasitemia | 0 | | 2004 | 2023 | 12.3 | low | 7 | 0 | 0 | 12 | 11 | 2 |
| Plasmodium falciparum Malaria | 0 | | 1997 | 2023 | 12.2 | high | 91 | 0 | 13 | 89 | 107 | 24 |
| Plasmodium vivax Malaria | 0 | | 1999 | 2016 | 14.1 | low | 6 | 0 | 1 | 5 | 7 | 0 |
| Pregnancy | 0 | | 2004 | 2023 | 11.2 | low | 5 | 0 | 0 | 8 | 13 | 1 |
| Pulmonary Consumption | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Purpura, Thrombocytopenic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Purpura, Thrombopenic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pyrexia | 0 | | 2006 | 2015 | 14.0 | low | 2 | 0 | 0 | 4 | 4 | 0 |
| Recrudescence | 0 | | 1997 | 2020 | 13.7 | low | 8 | 0 | 2 | 8 | 8 | 0 |
| Respiratory Distress Syndrome | 0 | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Rheumatoid Arthritis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Sensitivity and Specificity | 0 | | 1996 | 2020 | 14.1 | low | 0 | 0 | 1 | 6 | 4 | 0 |
| Sepsis | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Severe Acute Malnutrition | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Shock | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Splenic Rupture | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stomach Ulcer | 0 | | 2018 | 2020 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Thrombocytopenia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thrombopenia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Toxoplasmosis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Trypanosomiasis, African | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tuberculosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tuberculosis, Pulmonary | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Urination Disorders | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Vomiting | 0 | | 2004 | 2010 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.PloS one, , Volume: 11, Issue:7, 2016
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 15, Issue:4, 2010
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:12, 2006
Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:11, 2004
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.Tropical medicine & international health : TM & IH, , Volume: 3, Issue:6, 1998
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.Lancet (London, England), , Volume: 365, Issue:9469
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.BMC infectious diseases, , 12-19, Volume: 17, Issue:1, 2017
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria.Emerging infectious diseases, , Volume: 22, Issue:8, 2016
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:4, 2006
The Impact of a Community Awareness Strategy on Caregiver Treatment Seeking Behaviour and Use of Artemether-Lumefantrine for Febrile Children in Rural Kenya.PloS one, , Volume: 10, Issue:7, 2015
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.PloS one, , Volume: 9, Issue:12, 2014
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 18, Issue:5, 2013
Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.Tanzania journal of health research, , Volume: 14, Issue:2, 2012
The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 13, Issue:4, 2008
The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets.BMC public health, , Dec-29, Volume: 6, 2006
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:8, 2006
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Knowledge and practices of private pharmacy auxiliaries on malaria in Abidjan, Côte d'Ivoire.Malaria journal, , Nov-02, Volume: 22, Issue:1, 2023
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.The Lancet. Infectious diseases, , Volume: 23, Issue:9, 2023
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.Malaria journal, , Jun-03, Volume: 22, Issue:1, 2023
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.Malaria journal, , May-26, Volume: 22, Issue:1, 2023
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.Malaria journal, , May-19, Volume: 22, Issue:1, 2023
Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy.Journal of pharmaceutical sciences, , Volume: 112, Issue:8, 2023
A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria.Macromolecular bioscience, , Volume: 23, Issue:5, 2023
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.Malaria journal, , Feb-19, Volume: 22, Issue:1, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.The Lancet. Infectious diseases, , Volume: 23, Issue:1, 2023
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.British journal of clinical pharmacology, , Volume: 88, Issue:2, 2022
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 123, 2022
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.The Journal of antimicrobial chemotherapy, , 10-28, Volume: 77, Issue:11, 2022
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children.International journal for parasitology. Drugs and drug resistance, , Volume: 19, 2022
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.Drug design, development and therapy, , Volume: 14, 2020
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5, 2020
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.Malaria journal, , Feb-11, Volume: 19, Issue:1, 2020
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.European journal of medicinal chemistry, , Feb-15, Volume: 188, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Development and in vitro/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery.Journal of liposome research, , Volume: 29, Issue:1, 2019
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound.Expert opinion on investigational drugs, , Volume: 27, Issue:10, 2018
Quality of the antimalarial medicine artemether - lumefantrine in 8 cities of the Democratic Republic of the Congo.Drug testing and analysis, , Volume: 10, Issue:10, 2018
Drugs in Development for Malaria.Drugs, , Volume: 78, Issue:9, 2018
Optimization and evaluation of lipid emulsions for intravenous co-delivery of artemether and lumefantrine in severe malaria treatment.Drug delivery and translational research, , Volume: 8, Issue:5, 2018
Level A in vitro-in vivo correlation: Application to establish a dissolution test for artemether and lumefantrine tablets.Journal of pharmaceutical and biomedical analysis, , Jun-05, Volume: 155, 2018
Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS.Journal of pharmaceutical and biomedical analysis, , Jun-05, Volume: 155, 2018
Market for Artemether-Lumefantrine to treat childhood malaria in a district of southern Mozambique.Health economics, , Volume: 26, Issue:12, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.Statistics in medicine, , Aug-30, Volume: 36, Issue:19, 2017
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene, , 02-01, Volume: 111, Issue:2, 2017
Engineering of microcomplex of artemether and lumefantrine for effective drug treatment in malaria.Artificial cells, nanomedicine, and biotechnology, , Volume: 45, Issue:8, 2017
In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine.Malaria journal, , 12-28, Volume: 16, Issue:1, 2017
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Nature microbiology, , Volume: 2, Issue:10, 2017
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Spontaneous splenic rupture from Plasmodium ovalae malaria.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
The Impact of Inventory Management on Stock-Outs of Essential Drugs in Sub-Saharan Africa: Secondary Analysis of a Field Experiment in Zambia.PloS one, , Volume: 11, Issue:5, 2016
Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda.The American journal of tropical medicine and hygiene, , Volume: 94, Issue:4, 2016
Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 110, Issue:10, 2016
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.Tropical medicine & international health : TM & IH, , Volume: 21, Issue:2, 2016
Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.International journal of pharmaceutics, , Sep-10, Volume: 511, Issue:1, 2016
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.Journal of infection in developing countries, , Jun-30, Volume: 10, Issue:6, 2016
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.The pharmacogenomics journal, , Volume: 16, Issue:1, 2016
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.Health research policy and systems, , Jun-01, Volume: 14, Issue:1, 2016
Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.Drug delivery, , Volume: 23, Issue:1, 2016
In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 97, Issue:Pt A, 2015
The Impact of a Community Awareness Strategy on Caregiver Treatment Seeking Behaviour and Use of Artemether-Lumefantrine for Febrile Children in Rural Kenya.PloS one, , Volume: 10, Issue:7, 2015
[Effect of a large scale community-based distribution of artemether-lumefantrine on its therapeutic efficacy among children living in a rural area of Burkina Faso].Bulletin de la Societe de pathologie exotique (1990), , Volume: 108, Issue:2, 2015
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.Malaria journal, , Apr-25, Volume: 14, 2015
Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Malaria journal, , Jan-28, Volume: 14, 2015
Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:1, 2015
Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 23, Issue:3, 2014
Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser knowledge and patient adherence.The American journal of tropical medicine and hygiene, , Volume: 91, Issue:4, 2014
Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:10, 2014
Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Parasitology, , Volume: 141, Issue:14, 2014
Plasmodium knowlesi infection imported to Germany, January 2013.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, , Oct-03, Volume: 18, Issue:40, 2013
Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.International journal of pharmaceutics, , Oct-15, Volume: 455, Issue:1-2, 2013
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.Drug safety, , Volume: 36, Issue:9, 2013
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.HIV medicine, , Volume: 14, Issue:7, 2013
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.Tanzania journal of health research, , Volume: 14, Issue:2, 2012
Why do Plasmodium malariae infections sometimes occur in spite of previous antimalarial medication?Parasitology research, , Volume: 111, Issue:2, 2012
Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure.PloS one, , Volume: 7, Issue:2, 2012
Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.The Journal of antimicrobial chemotherapy, , Volume: 67, Issue:10, 2012
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model.Experimental parasitology, , Volume: 127, Issue:2, 2011
Pharmacokinetics of antimalarials in pregnancy: a systematic review.Clinical pharmacokinetics, , Nov-01, Volume: 50, Issue:11, 2011
Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:10, 2011
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Plasmodium knowlesi reinfection in human.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:11, 2011
Presumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United States.The American journal of tropical medicine and hygiene, , Volume: 85, Issue:4, 2011
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.Proceedings of the National Academy of Sciences of the United States of America, , Nov-22, Volume: 108, Issue:47, 2011
Plasmodium species co-infection as a cause of treatment failure.Travel medicine and infectious disease, , Volume: 9, Issue:6, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
A semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies.Malaria journal, , Jan-29, Volume: 9, 2010
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.PloS one, , Jul-30, Volume: 5, Issue:7, 2010
Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.The American journal of tropical medicine and hygiene, , Volume: 83, Issue:4, 2010
Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in Ugandan patients without malaria.The American journal of tropical medicine and hygiene, , Volume: 80, Issue:5, 2009
First artemisinin-based antimalarial combination approved for U.S. market.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 66, Issue:10, 2009
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 49, Issue:8, 2009
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.PloS one, , Nov-17, Volume: 4, Issue:11, 2009
Antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Mar-19, Volume: 360, Issue:12, 2009
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.Experimental parasitology, , Volume: 122, Issue:3, 2009
Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?The American journal of tropical medicine and hygiene, , Volume: 80, Issue:1, 2009
An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria.Malaria journal, , Jan-28, Volume: 7, 2008
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.Malaria journal, , Jan-29, Volume: 7, 2008
Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine.Malaria journal, , Feb-05, Volume: 7, 2008
An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria.PloS one, , Jun-25, Volume: 3, Issue:6, 2008
Malaria case-management under artemether-lumefantrine treatment policy in Uganda.Malaria journal, , Sep-19, Volume: 7, 2008
Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria.Malaria journal, , Nov-05, Volume: 7, 2008
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.Clinical pharmacology and therapeutics, , Volume: 82, Issue:5, 2007
[Artemether-lumefantrine, treatment of child more than 5 years old uncomplicated malaria in Tsevie's hospital (Togo)].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 14, Issue:12, 2007
The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets.BMC public health, , Dec-29, Volume: 6, 2006
Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6-59 months old in Ghana.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:7, 2006
Examples of tropical disease control in the humanitarian medical programmes of MSF and Merlin.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 100, Issue:4, 2006
First Brazilian experience with the use of artemether-lumefantrine (Coartem) a fixed-dosed ACT combination.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:2, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:2, 2006
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:8, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Artemether-lumefantrine for uncomplicated malaria: a systematic review.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:2, 2004
[Malaria: prophylaxis, treatment, stand-by medication. A single mosquito bite suffices].MMW Fortschritte der Medizin, , Jun-17, Volume: 146, Issue:25, 2004
[Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil].Nederlands tijdschrift voor geneeskunde, , Feb-15, Volume: 147, Issue:7, 2003
New antimalarial drugs.Angewandte Chemie (International ed. in English), , Nov-10, Volume: 42, Issue:43, 2003
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.Clinical pharmacokinetics, , Volume: 37, Issue:2, 1999
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.British journal of clinical pharmacology, , Volume: 46, Issue:6, 1998
Effectiveness of trained community volunteers in improving knowledge and management of childhood malaria in a rural area of Rivers State, Nigeria.Nigerian journal of clinical practice, , Volume: 18, Issue:5
[Efficacy of mefloquine, halofantrine, and coarteme in the treatment of tropical malaria].Meditsinskaia parazitologiia i parazitarnye bolezni, , Issue:1
Suspected allergy to artemether-lumefantrine treatment of malaria.Journal of travel medicine, , Volume: 10, Issue:5
Trends in antimalarial prescriptions in Australia 2002 to 2005.Journal of travel medicine, , Volume: 15, Issue:5
Community effectiveness of artemisinin-based combination therapy for malaria in rural southwestern Nigeria.International quarterly of community health education, , Volume: 29, Issue:1
Late manifestation of a mixed Plasmodium falciparum and Plasmodium malariae infection in a non-immune toddler after traveling to Chad.Travel medicine and infectious disease, , Volume: 14, Issue:5
Knowledge and practices of private pharmacy auxiliaries on malaria in Abidjan, Côte d'Ivoire.Malaria journal, , Nov-02, Volume: 22, Issue:1, 2023
Molecular surveillance of the Pfmdr1 N86Y allele among Congolese pregnant women with asymptomatic malaria.Malaria journal, , May-08, Volume: 19, Issue:1, 2020
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.Drug design, development and therapy, , Volume: 14, 2020
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.Antimicrobial agents and chemotherapy, , Volume: 62, Issue:10, 2018
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.Malaria journal, , 07-03, Volume: 16, Issue:1, 2017
Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 107, Issue:6, 2016
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Antimicrobial agents and chemotherapy, , Dec-14, Volume: 60, Issue:3, 2015
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:10, 2015
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:10, 2013
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.Drug safety, , Volume: 36, Issue:9, 2013
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Malaria journal, , Aug-22, Volume: 11, 2012
Pharmacokinetics of antimalarials in pregnancy: a systematic review.Clinical pharmacokinetics, , Nov-01, Volume: 50, Issue:11, 2011
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:9, 2009
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.PLoS medicine, , Dec-23, Volume: 5, Issue:12, 2008
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.Clinical pharmacology and therapeutics, , Volume: 82, Issue:5, 2007
Examples of tropical disease control in the humanitarian medical programmes of MSF and Merlin.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 100, Issue:4, 2006
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?Tropical medicine & international health : TM & IH, , Volume: 11, Issue:4, 2006
Artemisinin-based combinations.Current opinion in infectious diseases, , Volume: 18, Issue:6, 2005
[Malaria: prophylaxis, treatment, stand-by medication. A single mosquito bite suffices].MMW Fortschritte der Medizin, , Jun-17, Volume: 146, Issue:25, 2004
Severe acute respiratory distress syndrome secondary to Plasmodium vivax malaria.JPMA. The Journal of the Pakistan Medical Association, , Volume: 66, Issue:3, 2016
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study.Biomedical chromatography : BMC, , Volume: 34, Issue:9, 2020
A sensitive, high-throughput, and ecofriendly method for the determination of lumefantrine, artemether, and its active metabolite dihydroartemisinin by supercritical fluid chromatography and tandem mass spectrometry.Journal of separation science, , Volume: 41, Issue:12, 2018
Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study.Malaria journal, , Apr-22, Volume: 14, 2015
Development and validation of a LC-MS/MS method for the quantitation of lumefantrine in mouse whole blood and plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Mar-15, Volume: 985, 2015
A semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies.Malaria journal, , Jan-29, Volume: 9, 2010
Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection.Journal of pharmaceutical and biomedical analysis, , Nov-04, Volume: 48, Issue:3, 2008
An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria.Malaria journal, , Jan-28, Volume: 7, 2008
Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper.Journal of pharmaceutical and biomedical analysis, , Oct-18, Volume: 45, Issue:2, 2007
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:8, 2006
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?Tropical medicine & international health : TM & IH, , Volume: 11, Issue:4, 2006
Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.Journal of chromatography. B, Biomedical applications, , Jun-07, Volume: 681, Issue:2, 1996
Antimalarial combination therapies increase gastric ulcers through an imbalance of basic antioxidative-oxidative enzymes in male Wistar rats.BMC research notes, , Apr-23, Volume: 13, Issue:1, 2020
Effects of artemisinin, with or without lumefantrine and amodiaquine on gastric ulcer healing in rat.Journal of basic and clinical physiology and pharmacology, , 09-25, Volume: 29, Issue:5, 2018
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5, 2020
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion.Turkiye parazitolojii dergisi, , Volume: 41, Issue:4, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.Statistics in medicine, , Aug-30, Volume: 36, Issue:19, 2017
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.BMC infectious diseases, , Jan-27, Volume: 16, 2016
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.The pharmacogenomics journal, , Volume: 16, Issue:1, 2016
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.Malaria journal, , Apr-25, Volume: 14, 2015
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.AIDS (London, England), , Mar-27, Volume: 27, Issue:6, 2013
Are artemisinin-based combination therapies effective against Plasmodium malariae?The Journal of antimicrobial chemotherapy, , Volume: 68, Issue:6, 2013
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.HIV medicine, , Volume: 14, Issue:7, 2013
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.The Journal of infectious diseases, , Oct-01, Volume: 194, Issue:7, 2006
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 181, 2023
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.The Lancet. Infectious diseases, , Volume: 23, Issue:9, 2023
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.Malaria journal, , Jun-03, Volume: 22, Issue:1, 2023
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.Malaria journal, , May-26, Volume: 22, Issue:1, 2023
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.Malaria journal, , May-19, Volume: 22, Issue:1, 2023
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.Malaria journal, , Feb-19, Volume: 22, Issue:1, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.The Lancet. Infectious diseases, , Volume: 23, Issue:1, 2023
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.British journal of clinical pharmacology, , Volume: 88, Issue:2, 2022
[no title available]Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 123, 2022
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.The Journal of antimicrobial chemotherapy, , 10-28, Volume: 77, Issue:11, 2022
Making data map-worthy-enhancing routine malaria data to support surveillance and mapping of Plasmodium falciparum anti-malarial resistance in a pre-elimination sub-Saharan African setting: a molecular and spatiotemporal epidemiology study.Malaria journal, , Jun-29, Volume: 21, Issue:1, 2022
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children.International journal for parasitology. Drugs and drug resistance, , Volume: 19, 2022
Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT.PLoS biology, , Volume: 20, Issue:5, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.Antimicrobial agents and chemotherapy, , 01-18, Volume: 66, Issue:1, 2022
Artemether and lumefantrine dissolving microneedle patches with improved pharmacokinetic performance and antimalarial efficacy in mice infected with Plasmodium yoelii.Journal of controlled release : official journal of the Controlled Release Society, , 05-10, Volume: 333, 2021
Malaria in an asylum seeker paediatric liver transplant recipient: diagnostic challenges for migrant population.Journal of infection in developing countries, , 01-31, Volume: 15, Issue:1, 2021
Fatal case of delayed-onset haemolytic anaemia after oral artemether-lumefantrine.BMJ case reports, , Nov-19, Volume: 14, Issue:11, 2021
[no title available]ACS infectious diseases, , 11-12, Volume: 7, Issue:11, 2021
Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage.International journal for parasitology. Drugs and drug resistance, , Volume: 17, 2021
Drug susceptibility of The Lancet. Microbe, , Volume: 2, Issue:9, 2021
Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross.International journal for parasitology. Drugs and drug resistance, , Volume: 14, 2020
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal.International journal of antimicrobial agents, , Volume: 56, Issue:6, 2020
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.Drugs in R&D, , Volume: 20, Issue:3, 2020
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso.Malaria journal, , Jan-06, Volume: 19, Issue:1, 2020
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.Transactions of the Royal Society of Tropical Medicine and Hygiene, , 11-01, Volume: 113, Issue:11, 2019
Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers Antimicrobial agents and chemotherapy, , Volume: 63, Issue:9, 2019
Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.Malaria journal, , Jun-24, Volume: 18, Issue:1, 2019
Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Clinical pharmacology and therapeutics, , Volume: 106, Issue:6, 2019
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews, , 01-08, Volume: 1, 2019
Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:3, 2019
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.PloS one, , Volume: 14, Issue:9, 2019
Lack of significant recovery of chloroquine sensitivity in Plasmodium falciparum parasites following discontinuance of chloroquine use in Papua New Guinea.Malaria journal, , Nov-26, Volume: 17, Issue:1, 2018
Molecular Evidence for The American journal of tropical medicine and hygiene, , Volume: 99, Issue:6, 2018
A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria.BMC infectious diseases, , 08-13, Volume: 18, Issue:1, 2018
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.Antimicrobial agents and chemotherapy, , Volume: 62, Issue:10, 2018
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, , Volume: 63, 2018
Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China-Myanmar border reveals persistent circulation of multidrug resistant parasites.International journal for parasitology. Drugs and drug resistance, , Volume: 8, Issue:2, 2018
Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.PloS one, , Volume: 13, Issue:2, 2018
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.Malaria journal, , Jan-25, Volume: 17, Issue:1, 2018
Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 24, Issue:3, 2018
Enhanced antimalalarial activity of a prolonged release in situ gel of arteether-lumefantrine in a murine model.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 123, 2018
Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.Malaria journal, , Feb-20, Volume: 17, Issue:1, 2018
[no title available]The Indian journal of medical research, , Volume: 146, Issue:5, 2017
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion.Turkiye parazitolojii dergisi, , Volume: 41, Issue:4, 2017
In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine.Malaria journal, , 12-28, Volume: 16, Issue:1, 2017
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.BMC infectious diseases, , 12-19, Volume: 17, Issue:1, 2017
Sustained Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Changing Antimalarial Drug Sensitivities in Uganda.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Nature microbiology, , Volume: 2, Issue:10, 2017
Plasmodium falciparum in vitro continuous culture conditions: A comparison of parasite susceptibility and tolerance to anti-malarial drugs throughout the asexual intra-erythrocytic life cycle.International journal for parasitology. Drugs and drug resistance, , Volume: 7, Issue:3, 2017
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.Malaria journal, , 07-03, Volume: 16, Issue:1, 2017
Reply to van der Pluijm et al., "Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures".Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.Pharmacogenomics, , Volume: 18, Issue:10, 2017
Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia.PloS one, , Volume: 12, Issue:4, 2017
The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Aug-01, Volume: 65, Issue:3, 2017
Artemether-Lumefantrine Treatment Failure in Nonimmune European Travelers With Plasmodium falciparum Malaria: Do We Need to Reconsider Dosing in Patients From Nonendemic Regions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-15, Volume: 64, Issue:10, 2017
pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.Expert review of anti-infective therapy, , Volume: 15, Issue:6, 2017
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.The Lancet. Infectious diseases, , Volume: 17, Issue:5, 2017
Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.Tropical medicine & international health : TM & IH, , Volume: 22, Issue:4, 2017
Association between Polymorphisms in the PfAntimicrobial agents and chemotherapy, , Volume: 61, Issue:3, 2017
Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.The Journal of infectious diseases, , 02-15, Volume: 215, Issue:4, 2017
[Elimination in South-East Asia? The role of antimalarial drugs].Bulletin de l'Academie nationale de medecine, , Volume: 200, Issue:3, 2016
Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 107, Issue:6, 2016
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial.PloS one, , Volume: 11, Issue:9, 2016
West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia.The American journal of tropical medicine and hygiene, , Nov-02, Volume: 95, Issue:5, 2016
Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.Acta tropica, , Volume: 164, 2016
In vitro effects of co-incubation of blood with artemether/lumefantrine & vitamin C on the viscosity & elasticity of blood.The Indian journal of medical research, , Volume: 143, Issue:5, 2016
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8, 2016
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria.Emerging infectious diseases, , Volume: 22, Issue:8, 2016
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.The Lancet. Infectious diseases, , Volume: 16, Issue:10, 2016
Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.PloS one, , Volume: 11, Issue:7, 2016
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.Health research policy and systems, , Jun-01, Volume: 14, Issue:1, 2016
Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.BMC medicine, , Mar-08, Volume: 14, 2016
A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Apr-15, Volume: 62, Issue:8, 2016
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin.Malaria journal, , Jan-22, Volume: 15, 2016
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Antimicrobial agents and chemotherapy, , Dec-14, Volume: 60, Issue:3, 2015
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.BMC medicine, , Sep-18, Volume: 13, 2015
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:10, 2015
[Treated with Artemether-Lumefantrine Five Evaluation of P. Falciparum Malaria Cases in Terms of Hyponatremia and Thrombocytopenia].Turkiye parazitolojii dergisi, , Volume: 39, Issue:2, 2015
The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine.Expert review of anti-infective therapy, , Volume: 13, Issue:8, 2015
Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3, 2015
Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:2, 2015
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.PLoS medicine, , Volume: 11, Issue:12, 2014
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.PloS one, , Volume: 9, Issue:12, 2014
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Nature communications, , Nov-26, Volume: 5, 2014
Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania.Malaria journal, , Sep-20, Volume: 13, 2014
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.Malaria journal, , Sep-19, Volume: 13, 2014
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:12, 2014
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.The American journal of tropical medicine and hygiene, , Volume: 91, Issue:4, 2014
Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar.The Journal of antimicrobial chemotherapy, , Volume: 69, Issue:8, 2014
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews, , Mar-04, Issue:3, 2014
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.Journal of biomolecular screening, , Volume: 19, Issue:6, 2014
Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Expert opinion on pharmacotherapy, , Volume: 14, Issue:5, 2013
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 56, Issue:10, 2013
Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.PloS one, , Volume: 8, Issue:1, 2013
Are artemisinin-based combination therapies effective against Plasmodium malariae?The Journal of antimicrobial chemotherapy, , Volume: 68, Issue:6, 2013
Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.Clinical pharmacokinetics, , Volume: 52, Issue:3, 2013
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.The Southeast Asian journal of tropical medicine and public health, , Volume: 44 Suppl 1, 2013
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:10, 2013
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.PloS one, , Volume: 8, Issue:5, 2013
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:7, 2013
Modulation of PF10_0355 (MSPDBL2) alters Plasmodium falciparum response to antimalarial drugs.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:7, 2013
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 18, Issue:5, 2013
Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial.Revista da Sociedade Brasileira de Medicina Tropical, , Volume: 45, Issue:6, 2012
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Malaria journal, , Aug-22, Volume: 11, 2012
Increased urinary frequency: an unusual presentation of Plasmodium falciparum malaria.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 23, Issue:4, 2012
Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique.Colloids and surfaces. B, Biointerfaces, , Jun-15, Volume: 95, 2012
Successful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.The American journal of tropical medicine and hygiene, , Volume: 86, Issue:3, 2012
Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 86, Issue:3, 2012
Falciparum--the masquerader.JPMA. The Journal of the Pakistan Medical Association, , Volume: 62, Issue:1, 2012
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.Malaria journal, , Dec-16, Volume: 10, 2011
Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy.The American journal of tropical medicine and hygiene, , Volume: 85, Issue:6, 2011
Plasmodium species co-infection as a cause of treatment failure.Travel medicine and infectious disease, , Volume: 9, Issue:6, 2011
The pharmacogenetics of antimalaria artemisinin combination therapy.Expert opinion on drug metabolism & toxicology, , Volume: 7, Issue:10, 2011
Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.Malaria journal, , Jul-08, Volume: 10, 2011
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:9, 2011
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.PloS one, , Volume: 6, Issue:5, 2011
Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum.PLoS genetics, , Volume: 7, Issue:4, 2011
Automated erythrocytapheresis for severe falciparum malaria.Internal medicine journal, , Volume: 41, Issue:1a, 2011
Detecting adenosine triphosphatase 6 (pfATP6) point mutations that may be associated with Plasmodium falciparum resistance to artemisinin: prevalence at baseline, before policy change in Uganda.Tanzania journal of health research, , Volume: 13, Issue:1, 2011
Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.Bioorganic & medicinal chemistry, , Dec-15, Volume: 19, Issue:24, 2011
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:11, 2010
Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan.Annals of tropical medicine and parasitology, , Volume: 104, Issue:4, 2010
Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial.The Journal of infectious diseases, , Aug-15, Volume: 202, Issue:3, 2010
Artemisinin-based combination therapies and their introduction in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 16, Issue:6, 2010
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.Lancet (London, England), , Apr-24, Volume: 375, Issue:9724, 2010
Pyronaridine-artesunate for uncomplicated falciparum malaria.Lancet (London, England), , Apr-24, Volume: 375, Issue:9724, 2010
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:5, 2010
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.Journal of tropical pediatrics, , Volume: 56, Issue:6, 2010
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 15, Issue:4, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma.Bioanalysis, , Volume: 1, Issue:1, 2009
Cardiac complication after experimental human malaria infection: a case report.Malaria journal, , Dec-03, Volume: 8, 2009
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.PloS one, , Nov-17, Volume: 4, Issue:11, 2009
Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria.PloS one, , Aug-19, Volume: 4, Issue:8, 2009
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial.The Journal of infectious diseases, , Jul-01, Volume: 200, Issue:1, 2009
Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection.British journal of haematology, , Volume: 145, Issue:5, 2009
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:12, 2009
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:9, 2009
High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria.Tropical medicine & international health : TM & IH, , Volume: 13, Issue:5, 2008
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.PLoS medicine, , Dec-23, Volume: 5, Issue:12, 2008
Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.Wiener klinische Wochenschrift, , Volume: 120, Issue:19-20 Supp, 2008
A trial of combination antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Dec-11, Volume: 359, Issue:24, 2008
A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.The American journal of tropical medicine and hygiene, , Volume: 79, Issue:5, 2008
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.Malaria journal, , Sep-16, Volume: 7, 2008
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?Malaria journal, , Sep-15, Volume: 7, 2008
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children.Malaria journal, , Aug-09, Volume: 7, 2008
[Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Feb-28, Volume: 26, Issue:1, 2008
Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 102, Issue:9, 2008
Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children.Chemotherapy, , Volume: 54, Issue:3, 2008
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.PloS one, , Jun-11, Volume: 3, Issue:6, 2008
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.Malaria journal, , Nov-11, Volume: 6, 2007
In vitro interaction of dihydroartemisin and lumefantrine in clinical field isolates from Bangladesh.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
[Treatment of falciparum malaria with artemether-lumefantrine according to a 5-day schedule: results of a study in 21 patients and recommendations].Nederlands tijdschrift voor geneeskunde, , Oct-06, Volume: 151, Issue:40, 2007
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal.Malaria journal, , Jun-14, Volume: 6, 2007
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:8, 2007
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].Bulletin de la Societe de pathologie exotique (1990), , Volume: 100, Issue:1, 2007
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2, 2007
How much fat is necessary to optimize lumefantrine oral bioavailability?Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2, 2007
In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos).The American journal of tropical medicine and hygiene, , Volume: 76, Issue:2, 2007
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:3, 2007
Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria.Expert opinion on pharmacotherapy, , Volume: 8, Issue:1, 2007
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:12, 2006
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo.Malaria journal, , Nov-24, Volume: 5, 2006
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:4, 2006
Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?Malaria journal, , Oct-04, Volume: 5, 2006
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.The Journal of infectious diseases, , Oct-01, Volume: 194, Issue:7, 2006
Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia.Malaria journal, , Aug-28, Volume: 5, 2006
Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults.Malaria journal, , Aug-21, Volume: 5, 2006
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.Travel medicine and infectious disease, , Volume: 4, Issue:2, 2006
From chloroquine to artemisinin-based combination therapy: the Sudanese experience.Malaria journal, , Jul-31, Volume: 5, 2006
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.Malaria journal, , Jul-19, Volume: 5, 2006
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin.The Journal of infectious diseases, , Aug-15, Volume: 194, Issue:4, 2006
High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:1, 2006
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.Malaria journal, , May-16, Volume: 5, 2006
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Jun-01, Volume: 42, Issue:11, 2006
[Malaria: a medical and economic problem].Presse medicale (Paris, France : 1983), , Volume: 35, Issue:4 Pt 1, 2006
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?Tropical medicine & international health : TM & IH, , Volume: 11, Issue:4, 2006
The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan.Annals of tropical medicine and parasitology, , Volume: 100, Issue:1, 2006
Successful treatment of Plasmodium falciparum malaria with a six-dose regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon region of Brazil.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:1, 2006
Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia.East African medical journal, , Volume: 82, Issue:8, 2005
Artemisinin-based combinations.Current opinion in infectious diseases, , Volume: 18, Issue:6, 2005
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa.PLoS medicine, , Volume: 2, Issue:11, 2005
A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.Malaria journal, , Sep-22, Volume: 4, 2005
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 41, Issue:8, 2005
Coartem (artemether-lumefantrine) in Africa: the beginning of the end?The Journal of infectious diseases, , Oct-01, Volume: 192, Issue:7, 2005
Malaria: uncomplicated, caused by Plasmodium falciparum.Clinical evidence, , Issue:13, 2005
Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 99, Issue:10, 2005
Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.Proteomics, , Volume: 5, Issue:7, 2005
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).The Journal of infectious diseases, , Mar-15, Volume: 191, Issue:6, 2005
In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand.Wiener klinische Wochenschrift, , Volume: 116 Suppl 4, 2004
Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda.The American journal of tropical medicine and hygiene, , Volume: 71, Issue:5, 2004
Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:11, 2004
Efficacy of artemether-lumefantrine treatment in patients with acute uncomplicated Falciparum malaria in Mayotte, a French collectivity of the Comoros Archipelago.Parasite (Paris, France), , Volume: 11, Issue:3, 2004
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 39, Issue:8, 2004
Coartemether (artemether and lumefantrine): an oral antimalarial drug.Expert review of anti-infective therapy, , Volume: 2, Issue:2, 2004
Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:9, 2004
Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan.Annals of tropical medicine and parasitology, , Volume: 98, Issue:6, 2004
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].Tropical medicine & international health : TM & IH, , Volume: 9, Issue:6, 2004
Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand.The Southeast Asian journal of tropical medicine and public health, , Volume: 34, Issue:3, 2003
Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand.The Southeast Asian journal of tropical medicine and public health, , Volume: 34, Issue:2, 2003
Artemether-lumefantrine for treating uncomplicated falciparum malaria.The Cochrane database of systematic reviews, , Issue:2, 2003
The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria.Fundamental & clinical pharmacology, , Volume: 17, Issue:2, 2003
[Riamet: a new antimalarial for curative treatment of malaria].Medecine tropicale : revue du Corps de sante colonial, , Volume: 62, Issue:5, 2002
[Clinical comparative trial of co-artemether and benflumetol (two formulations) in the treatment of falciparum malaria].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Volume: 18, Issue:3, 2000
In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether.British journal of clinical pharmacology, , Volume: 49, Issue:5, 2000
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 44, Issue:3, 2000
No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 61, Issue:6, 1999
Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.International journal of clinical pharmacology research, , Volume: 19, Issue:2, 1999
Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria.International journal of antimicrobial agents, , Volume: 12, Issue:2, 1999
A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand.The American journal of tropical medicine and hygiene, , Volume: 60, Issue:2, 1999
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs.Antimicrobial agents and chemotherapy, , Volume: 43, Issue:2, 1999
Positioning, labelling, and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team.Medecine tropicale : revue du Corps de sante colonial, , Volume: 58, Issue:3 Suppl, 1998
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.Tropical medicine & international health : TM & IH, , Volume: 3, Issue:6, 1998
A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.The American journal of tropical medicine and hygiene, , Volume: 58, Issue:5, 1998
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 42, Issue:1, 1998
Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697.The Journal of infectious diseases, , Volume: 176, Issue:4, 1997
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.The American journal of tropical medicine and hygiene, , Volume: 64, Issue:5-6
Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial.Lancet (London, England), , Volume: 365, Issue:9469
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.Lancet (London, England), , Volume: 365, Issue:9469
Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina FasoAnnals of parasitology, , Volume: 63, Issue:2
Analytic Study In Patients Presenting To A Tertiary Care Hospital Regarding The Artemether-Lumefantrine Induced Qtc Interval Changes In ECG.Journal of Ayub Medical College, Abbottabad : JAMC, , Volume: 29, Issue:1
Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 97, Issue:4
[Drug resistant tropical malaria in the Republic of Guinea (West Africa)].Meditsinskaia parazitologiia i parazitarnye bolezni, , Issue:2
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:5
An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:4
The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol).Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 92, Issue:5
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:12, 2016
Severe acute respiratory distress syndrome secondary to Plasmodium vivax malaria.JPMA. The Journal of the Pakistan Medical Association, , Volume: 66, Issue:3, 2016
Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.The Southeast Asian journal of tropical medicine and public health, , Volume: 44 Suppl 1, 2013
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 56, Issue:10, 2013
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.PloS one, , Volume: 8, Issue:5, 2013
Hemophagocytic syndrome associated with severe Plasmodium vivax malaria in a child in Bikaner (northwestern India).Journal of vector borne diseases, , Volume: 50, Issue:4, 2013
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
A trial of combination antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Dec-11, Volume: 359, Issue:24, 2008
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.The Korean journal of parasitology, , Volume: 45, Issue:2, 2007
Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand.Wiener klinische Wochenschrift, , Volume: 116 Suppl 4, 2004
In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand.Wiener klinische Wochenschrift, , Volume: 115 Suppl 3, 2003
[Observation on efficacy of artemether compound against vivax malaria].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Volume: 17, Issue:3, 1999
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:2, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.Travel medicine and infectious disease, , Volume: 4, Issue:2, 2006
Plasmodium knowlesi infection imported to Germany, January 2013.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, , Oct-03, Volume: 18, Issue:40, 2013
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria.Macromolecular bioscience, , Volume: 23, Issue:5, 2023
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.Malaria journal, , Feb-11, Volume: 19, Issue:1, 2020
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene, , 02-01, Volume: 111, Issue:2, 2017
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.Journal of infection in developing countries, , Jun-30, Volume: 10, Issue:6, 2016
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8, 2016
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.The Southeast Asian journal of tropical medicine and public health, , Volume: 44 Suppl 1, 2013
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.PloS one, , Volume: 8, Issue:5, 2013
Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.International journal of pharmaceutics, , Oct-15, Volume: 455, Issue:1-2, 2013
Successful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.The American journal of tropical medicine and hygiene, , Volume: 86, Issue:3, 2012
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Automated erythrocytapheresis for severe falciparum malaria.Internal medicine journal, , Volume: 41, Issue:1a, 2011
Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial.The Journal of infectious diseases, , Aug-15, Volume: 202, Issue:3, 2010
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.Experimental parasitology, , Volume: 122, Issue:3, 2009
Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection.British journal of haematology, , Volume: 145, Issue:5, 2009
Cardiac complication after experimental human malaria infection: a case report.Malaria journal, , Dec-03, Volume: 8, 2009
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?Malaria journal, , Sep-15, Volume: 7, 2008
Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria.Malaria journal, , Nov-05, Volume: 7, 2008
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.The Korean journal of parasitology, , Volume: 45, Issue:2, 2007
Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?Malaria journal, , Oct-04, Volume: 5, 2006
Artemether-lumefantrine for uncomplicated malaria: a systematic review.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:2, 2004
Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:11, 2004
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:2, 2006
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.Travel medicine and infectious disease, , Volume: 4, Issue:2, 2006
Plasmodium knowlesi infection imported to Germany, January 2013.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, , Oct-03, Volume: 18, Issue:40, 2013
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion.Turkiye parazitolojii dergisi, , Volume: 41, Issue:4, 2017
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.The pharmacogenomics journal, , Volume: 16, Issue:1, 2016
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Parasitology, , Volume: 141, Issue:14, 2014
Plasmodium species co-infection as a cause of treatment failure.Travel medicine and infectious disease, , Volume: 9, Issue:6, 2011
Late manifestation of a mixed Plasmodium falciparum and Plasmodium malariae infection in a non-immune toddler after traveling to Chad.Travel medicine and infectious disease, , Volume: 14, Issue:5
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.Malaria journal, , May-19, Volume: 22, Issue:1, 2023
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5, 2020
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.Malaria journal, , Feb-11, Volume: 19, Issue:1, 2020
Neurotoxicity assessment of artemether in juvenile rats.Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 98, Issue:2, 2013
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.Malaria journal, , Dec-16, Volume: 10, 2011
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1, 2010
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.Travel medicine and infectious disease, , Volume: 4, Issue:2, 2006
A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria.Macromolecular bioscience, , Volume: 23, Issue:5, 2023
Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: preclinical investigation on NK-65 Expert opinion on drug delivery, , Volume: 18, Issue:10, 2021
Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.Parasites & vectors, , Jul-20, Volume: 13, Issue:1, 2020
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Enhanced antimalalarial activity of a prolonged release in situ gel of arteether-lumefantrine in a murine model.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 123, 2018
Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 107, Issue:6, 2016
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.Journal of infection in developing countries, , Jun-30, Volume: 10, Issue:6, 2016
Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Malaria journal, , Jan-28, Volume: 14, 2015
In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 97, Issue:Pt A, 2015
Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.International journal of pharmaceutics, , Oct-15, Volume: 455, Issue:1-2, 2013
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.Experimental parasitology, , Volume: 122, Issue:3, 2009
The Impact of a Community Awareness Strategy on Caregiver Treatment Seeking Behaviour and Use of Artemether-Lumefantrine for Febrile Children in Rural Kenya.PloS one, , Volume: 10, Issue:7, 2015
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.PloS one, , Volume: 9, Issue:12, 2014
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 18, Issue:5, 2013
Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.Tanzania journal of health research, , Volume: 14, Issue:2, 2012
The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 13, Issue:4, 2008
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:8, 2006
The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets.BMC public health, , Dec-29, Volume: 6, 2006
Knowledge and practices of private pharmacy auxiliaries on malaria in Abidjan, Côte d'Ivoire.Malaria journal, , Nov-02, Volume: 22, Issue:1, 2023
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.The Lancet. Infectious diseases, , Volume: 23, Issue:9, 2023
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.Malaria journal, , Jun-03, Volume: 22, Issue:1, 2023
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.Malaria journal, , May-26, Volume: 22, Issue:1, 2023
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.Malaria journal, , May-19, Volume: 22, Issue:1, 2023
Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy.Journal of pharmaceutical sciences, , Volume: 112, Issue:8, 2023
A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria.Macromolecular bioscience, , Volume: 23, Issue:5, 2023
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.Malaria journal, , Feb-19, Volume: 22, Issue:1, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.The Lancet. Infectious diseases, , Volume: 23, Issue:1, 2023
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.British journal of clinical pharmacology, , Volume: 88, Issue:2, 2022
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 123, 2022
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.The Journal of antimicrobial chemotherapy, , 10-28, Volume: 77, Issue:11, 2022
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children.International journal for parasitology. Drugs and drug resistance, , Volume: 19, 2022
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.Drug design, development and therapy, , Volume: 14, 2020
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5, 2020
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.Malaria journal, , Feb-11, Volume: 19, Issue:1, 2020
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 06-11, Volume: 63, Issue:11, 2020
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.European journal of medicinal chemistry, , Feb-15, Volume: 188, 2020
Development and in vitro/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery.Journal of liposome research, , Volume: 29, Issue:1, 2019
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
Quality of the antimalarial medicine artemether - lumefantrine in 8 cities of the Democratic Republic of the Congo.Drug testing and analysis, , Volume: 10, Issue:10, 2018
Drugs in Development for Malaria.Drugs, , Volume: 78, Issue:9, 2018
Optimization and evaluation of lipid emulsions for intravenous co-delivery of artemether and lumefantrine in severe malaria treatment.Drug delivery and translational research, , Volume: 8, Issue:5, 2018
Level A in vitro-in vivo correlation: Application to establish a dissolution test for artemether and lumefantrine tablets.Journal of pharmaceutical and biomedical analysis, , Jun-05, Volume: 155, 2018
Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS.Journal of pharmaceutical and biomedical analysis, , Jun-05, Volume: 155, 2018
The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound.Expert opinion on investigational drugs, , Volume: 27, Issue:10, 2018
In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine.Malaria journal, , 12-28, Volume: 16, Issue:1, 2017
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Nature microbiology, , Volume: 2, Issue:10, 2017
Engineering of microcomplex of artemether and lumefantrine for effective drug treatment in malaria.Artificial cells, nanomedicine, and biotechnology, , Volume: 45, Issue:8, 2017
Market for Artemether-Lumefantrine to treat childhood malaria in a district of southern Mozambique.Health economics, , Volume: 26, Issue:12, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.Statistics in medicine, , Aug-30, Volume: 36, Issue:19, 2017
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.Transactions of the Royal Society of Tropical Medicine and Hygiene, , 02-01, Volume: 111, Issue:2, 2017
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017
Spontaneous splenic rupture from Plasmodium ovalae malaria.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.Drug delivery, , Volume: 23, Issue:1, 2016
The Impact of Inventory Management on Stock-Outs of Essential Drugs in Sub-Saharan Africa: Secondary Analysis of a Field Experiment in Zambia.PloS one, , Volume: 11, Issue:5, 2016
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.Health research policy and systems, , Jun-01, Volume: 14, Issue:1, 2016
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.The pharmacogenomics journal, , Volume: 16, Issue:1, 2016
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.Journal of infection in developing countries, , Jun-30, Volume: 10, Issue:6, 2016
Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 110, Issue:10, 2016
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.Tropical medicine & international health : TM & IH, , Volume: 21, Issue:2, 2016
Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.International journal of pharmaceutics, , Sep-10, Volume: 511, Issue:1, 2016
Can Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda.The American journal of tropical medicine and hygiene, , Volume: 94, Issue:4, 2016
Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:1, 2015
Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Malaria journal, , Jan-28, Volume: 14, 2015
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.Malaria journal, , Apr-25, Volume: 14, 2015
[Effect of a large scale community-based distribution of artemether-lumefantrine on its therapeutic efficacy among children living in a rural area of Burkina Faso].Bulletin de la Societe de pathologie exotique (1990), , Volume: 108, Issue:2, 2015
The Impact of a Community Awareness Strategy on Caregiver Treatment Seeking Behaviour and Use of Artemether-Lumefantrine for Febrile Children in Rural Kenya.PloS one, , Volume: 10, Issue:7, 2015
In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 97, Issue:Pt A, 2015
Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 23, Issue:3, 2014
Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Parasitology, , Volume: 141, Issue:14, 2014
Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:10, 2014
Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser knowledge and patient adherence.The American journal of tropical medicine and hygiene, , Volume: 91, Issue:4, 2014
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.Drug safety, , Volume: 36, Issue:9, 2013
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.HIV medicine, , Volume: 14, Issue:7, 2013
Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.International journal of pharmaceutics, , Oct-15, Volume: 455, Issue:1-2, 2013
Plasmodium knowlesi infection imported to Germany, January 2013.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, , Oct-03, Volume: 18, Issue:40, 2013
Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.The Journal of antimicrobial chemotherapy, , Volume: 67, Issue:10, 2012
Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure.PloS one, , Volume: 7, Issue:2, 2012
Why do Plasmodium malariae infections sometimes occur in spite of previous antimalarial medication?Parasitology research, , Volume: 111, Issue:2, 2012
Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.Tanzania journal of health research, , Volume: 14, Issue:2, 2012
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Plasmodium species co-infection as a cause of treatment failure.Travel medicine and infectious disease, , Volume: 9, Issue:6, 2011
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.Proceedings of the National Academy of Sciences of the United States of America, , Nov-22, Volume: 108, Issue:47, 2011
Presumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United States.The American journal of tropical medicine and hygiene, , Volume: 85, Issue:4, 2011
Pharmacokinetics of antimalarials in pregnancy: a systematic review.Clinical pharmacokinetics, , Nov-01, Volume: 50, Issue:11, 2011
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:11, 2011
Plasmodium knowlesi reinfection in human.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:10, 2011
Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model.Experimental parasitology, , Volume: 127, Issue:2, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.The American journal of tropical medicine and hygiene, , Volume: 83, Issue:4, 2010
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.PloS one, , Jul-30, Volume: 5, Issue:7, 2010
A semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies.Malaria journal, , Jan-29, Volume: 9, 2010
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.PloS one, , Nov-17, Volume: 4, Issue:11, 2009
Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 49, Issue:8, 2009
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
First artemisinin-based antimalarial combination approved for U.S. market.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 66, Issue:10, 2009
Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in Ugandan patients without malaria.The American journal of tropical medicine and hygiene, , Volume: 80, Issue:5, 2009
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.Experimental parasitology, , Volume: 122, Issue:3, 2009
Antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Mar-19, Volume: 360, Issue:12, 2009
Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?The American journal of tropical medicine and hygiene, , Volume: 80, Issue:1, 2009
Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria.Malaria journal, , Nov-05, Volume: 7, 2008
Malaria case-management under artemether-lumefantrine treatment policy in Uganda.Malaria journal, , Sep-19, Volume: 7, 2008
An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria.PloS one, , Jun-25, Volume: 3, Issue:6, 2008
Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine.Malaria journal, , Feb-05, Volume: 7, 2008
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.Malaria journal, , Jan-29, Volume: 7, 2008
An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria.Malaria journal, , Jan-28, Volume: 7, 2008
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
[Artemether-lumefantrine, treatment of child more than 5 years old uncomplicated malaria in Tsevie's hospital (Togo)].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 14, Issue:12, 2007
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.Clinical pharmacology and therapeutics, , Volume: 82, Issue:5, 2007
The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets.BMC public health, , Dec-29, Volume: 6, 2006
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:8, 2006
First Brazilian experience with the use of artemether-lumefantrine (Coartem) a fixed-dosed ACT combination.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:2, 2006
Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6-59 months old in Ghana.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:7, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
A case-control auditory evaluation of patients treated with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:2, 2006
Examples of tropical disease control in the humanitarian medical programmes of MSF and Merlin.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 100, Issue:4, 2006
[Malaria: prophylaxis, treatment, stand-by medication. A single mosquito bite suffices].MMW Fortschritte der Medizin, , Jun-17, Volume: 146, Issue:25, 2004
Artemether-lumefantrine for uncomplicated malaria: a systematic review.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:2, 2004
New antimalarial drugs.Angewandte Chemie (International ed. in English), , Nov-10, Volume: 42, Issue:43, 2003
[Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil].Nederlands tijdschrift voor geneeskunde, , Feb-15, Volume: 147, Issue:7, 2003
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.Clinical pharmacokinetics, , Volume: 37, Issue:2, 1999
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.British journal of clinical pharmacology, , Volume: 46, Issue:6, 1998
Community effectiveness of artemisinin-based combination therapy for malaria in rural southwestern Nigeria.International quarterly of community health education, , Volume: 29, Issue:1
Late manifestation of a mixed Plasmodium falciparum and Plasmodium malariae infection in a non-immune toddler after traveling to Chad.Travel medicine and infectious disease, , Volume: 14, Issue:5
Suspected allergy to artemether-lumefantrine treatment of malaria.Journal of travel medicine, , Volume: 10, Issue:5
Trends in antimalarial prescriptions in Australia 2002 to 2005.Journal of travel medicine, , Volume: 15, Issue:5
[Efficacy of mefloquine, halofantrine, and coarteme in the treatment of tropical malaria].Meditsinskaia parazitologiia i parazitarnye bolezni, , Issue:1
Effectiveness of trained community volunteers in improving knowledge and management of childhood malaria in a rural area of Rivers State, Nigeria.Nigerian journal of clinical practice, , Volume: 18, Issue:5
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Malaria journal, , Aug-22, Volume: 11, 2012
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.Clinical pharmacology and therapeutics, , Volume: 82, Issue:5, 2007
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?Tropical medicine & international health : TM & IH, , Volume: 11, Issue:4, 2006
Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.Malaria journal, , Feb-11, Volume: 19, Issue:1, 2020
Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Clinical pharmacology and therapeutics, , Volume: 106, Issue:6, 2019
Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 24, Issue:3, 2018
Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.PloS one, , Volume: 11, Issue:7, 2016
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8, 2016
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.BMC medicine, , Sep-18, Volume: 13, 2015
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:10, 2015
Plasmodium knowlesi reinfection in human.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:5, 2010
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:3, 2009
A trial of combination antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Dec-11, Volume: 359, Issue:24, 2008
[Treatment of falciparum malaria with artemether-lumefantrine according to a 5-day schedule: results of a study in 21 patients and recommendations].Nederlands tijdschrift voor geneeskunde, , Oct-06, Volume: 151, Issue:40, 2007
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].Bulletin de la Societe de pathologie exotique (1990), , Volume: 100, Issue:1, 2007
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.Malaria journal, , Jul-19, Volume: 5, 2006
Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?Malaria journal, , Oct-04, Volume: 5, 2006
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
[Observation on efficacy of artemether compound against vivax malaria].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Volume: 17, Issue:3, 1999
Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697.The Journal of infectious diseases, , Volume: 176, Issue:4, 1997
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:5
Severe acute respiratory distress syndrome secondary to Plasmodium vivax malaria.JPMA. The Journal of the Pakistan Medical Association, , Volume: 66, Issue:3, 2016
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.Emerging infectious diseases, , Volume: 17, Issue:7, 2011
Antimalarial combination therapies increase gastric ulcers through an imbalance of basic antioxidative-oxidative enzymes in male Wistar rats.BMC research notes, , Apr-23, Volume: 13, Issue:1, 2020
Effects of artemisinin, with or without lumefantrine and amodiaquine on gastric ulcer healing in rat.Journal of basic and clinical physiology and pharmacology, , 09-25, Volume: 29, Issue:5, 2018
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.Malaria journal, , 07-03, Volume: 16, Issue:1, 2017
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Antimicrobial agents and chemotherapy, , Dec-14, Volume: 60, Issue:3, 2015
Pharmacokinetics of antimalarials in pregnancy: a systematic review.Clinical pharmacokinetics, , Nov-01, Volume: 50, Issue:11, 2011
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.PLoS medicine, , Dec-23, Volume: 5, Issue:12, 2008
Artemisinin-based combinations.Current opinion in infectious diseases, , Volume: 18, Issue:6, 2005
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5, 2020
Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.PloS one, , Volume: 13, Issue:8, 2018
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion.Turkiye parazitolojii dergisi, , Volume: 41, Issue:4, 2017
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.Statistics in medicine, , Aug-30, Volume: 36, Issue:19, 2017
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.BMC infectious diseases, , Jan-27, Volume: 16, 2016
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.The pharmacogenomics journal, , Volume: 16, Issue:1, 2016
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.Malaria journal, , Apr-25, Volume: 14, 2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Are artemisinin-based combination therapies effective against Plasmodium malariae?The Journal of antimicrobial chemotherapy, , Volume: 68, Issue:6, 2013
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.HIV medicine, , Volume: 14, Issue:7, 2013
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.AIDS (London, England), , Mar-27, Volume: 27, Issue:6, 2013
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.The Journal of infectious diseases, , Oct-01, Volume: 194, Issue:7, 2006
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.Malaria journal, , Jun-03, Volume: 22, Issue:1, 2023
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.Malaria journal, , May-26, Volume: 22, Issue:1, 2023
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.Malaria journal, , May-19, Volume: 22, Issue:1, 2023
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.Malaria journal, , Feb-19, Volume: 22, Issue:1, 2023
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.Malaria journal, , Jan-27, Volume: 22, Issue:1, 2023
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.Clinical pharmacology and therapeutics, , Volume: 113, Issue:3, 2023
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.The Lancet. Infectious diseases, , Volume: 23, Issue:1, 2023
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3, 2023
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 181, 2023
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.The Lancet. Infectious diseases, , Volume: 23, Issue:9, 2023
[no title available]Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 123, 2022
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.The Journal of antimicrobial chemotherapy, , 10-28, Volume: 77, Issue:11, 2022
Making data map-worthy-enhancing routine malaria data to support surveillance and mapping of Plasmodium falciparum anti-malarial resistance in a pre-elimination sub-Saharan African setting: a molecular and spatiotemporal epidemiology study.Malaria journal, , Jun-29, Volume: 21, Issue:1, 2022
The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children.International journal for parasitology. Drugs and drug resistance, , Volume: 19, 2022
Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT.PLoS biology, , Volume: 20, Issue:5, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.Antimicrobial agents and chemotherapy, , 01-18, Volume: 66, Issue:1, 2022
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.British journal of clinical pharmacology, , Volume: 88, Issue:2, 2022
Fatal case of delayed-onset haemolytic anaemia after oral artemether-lumefantrine.BMJ case reports, , Nov-19, Volume: 14, Issue:11, 2021
[no title available]ACS infectious diseases, , 11-12, Volume: 7, Issue:11, 2021
Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage.International journal for parasitology. Drugs and drug resistance, , Volume: 17, 2021
Drug susceptibility of The Lancet. Microbe, , Volume: 2, Issue:9, 2021
Artemether and lumefantrine dissolving microneedle patches with improved pharmacokinetic performance and antimalarial efficacy in mice infected with Plasmodium yoelii.Journal of controlled release : official journal of the Controlled Release Society, , 05-10, Volume: 333, 2021
Malaria in an asylum seeker paediatric liver transplant recipient: diagnostic challenges for migrant population.Journal of infection in developing countries, , 01-31, Volume: 15, Issue:1, 2021
Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross.International journal for parasitology. Drugs and drug resistance, , Volume: 14, 2020
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal.International journal of antimicrobial agents, , Volume: 56, Issue:6, 2020
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.Drugs in R&D, , Volume: 20, Issue:3, 2020
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2, 2020
In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso.Malaria journal, , Jan-06, Volume: 19, Issue:1, 2020
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.Transactions of the Royal Society of Tropical Medicine and Hygiene, , 11-01, Volume: 113, Issue:11, 2019
Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers Antimicrobial agents and chemotherapy, , Volume: 63, Issue:9, 2019
Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.Malaria journal, , Jun-24, Volume: 18, Issue:1, 2019
Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Clinical pharmacology and therapeutics, , Volume: 106, Issue:6, 2019
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews, , 01-08, Volume: 1, 2019
Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.Antimicrobial agents and chemotherapy, , Volume: 63, Issue:3, 2019
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.PloS one, , Volume: 14, Issue:9, 2019
Lack of significant recovery of chloroquine sensitivity in Plasmodium falciparum parasites following discontinuance of chloroquine use in Papua New Guinea.Malaria journal, , Nov-26, Volume: 17, Issue:1, 2018
Molecular Evidence for The American journal of tropical medicine and hygiene, , Volume: 99, Issue:6, 2018
A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria.BMC infectious diseases, , 08-13, Volume: 18, Issue:1, 2018
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.Antimicrobial agents and chemotherapy, , Volume: 62, Issue:10, 2018
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, , Volume: 63, 2018
Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China-Myanmar border reveals persistent circulation of multidrug resistant parasites.International journal for parasitology. Drugs and drug resistance, , Volume: 8, Issue:2, 2018
Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.Malaria journal, , Feb-20, Volume: 17, Issue:1, 2018
Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.PloS one, , Volume: 13, Issue:2, 2018
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.Malaria journal, , Jan-25, Volume: 17, Issue:1, 2018
Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 24, Issue:3, 2018
Enhanced antimalalarial activity of a prolonged release in situ gel of arteether-lumefantrine in a murine model.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 123, 2018
Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.Tropical medicine & international health : TM & IH, , Volume: 22, Issue:4, 2017
Association between Polymorphisms in the PfAntimicrobial agents and chemotherapy, , Volume: 61, Issue:3, 2017
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.The Lancet. Infectious diseases, , Volume: 17, Issue:5, 2017
Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.The Journal of infectious diseases, , 02-15, Volume: 215, Issue:4, 2017
[no title available]The Indian journal of medical research, , Volume: 146, Issue:5, 2017
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion.Turkiye parazitolojii dergisi, , Volume: 41, Issue:4, 2017
In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine.Malaria journal, , 12-28, Volume: 16, Issue:1, 2017
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.BMC infectious diseases, , 12-19, Volume: 17, Issue:1, 2017
Sustained Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Changing Antimalarial Drug Sensitivities in Uganda.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:12, 2017
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Nature microbiology, , Volume: 2, Issue:10, 2017
Plasmodium falciparum in vitro continuous culture conditions: A comparison of parasite susceptibility and tolerance to anti-malarial drugs throughout the asexual intra-erythrocytic life cycle.International journal for parasitology. Drugs and drug resistance, , Volume: 7, Issue:3, 2017
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.Malaria journal, , 07-03, Volume: 16, Issue:1, 2017
Reply to van der Pluijm et al., "Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures".Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.Pharmacogenomics, , Volume: 18, Issue:10, 2017
Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia.PloS one, , Volume: 12, Issue:4, 2017
The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Aug-01, Volume: 65, Issue:3, 2017
Artemether-Lumefantrine Treatment Failure in Nonimmune European Travelers With Plasmodium falciparum Malaria: Do We Need to Reconsider Dosing in Patients From Nonendemic Regions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 05-15, Volume: 64, Issue:10, 2017
pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.Expert review of anti-infective therapy, , Volume: 15, Issue:6, 2017
West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia.The American journal of tropical medicine and hygiene, , Nov-02, Volume: 95, Issue:5, 2016
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8, 2016
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria.Emerging infectious diseases, , Volume: 22, Issue:8, 2016
A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Apr-15, Volume: 62, Issue:8, 2016
Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.Acta tropica, , Volume: 164, 2016
Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.BMC medicine, , Mar-08, Volume: 14, 2016
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin.Malaria journal, , Jan-22, Volume: 15, 2016
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial.PloS one, , Volume: 11, Issue:9, 2016
Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.PloS one, , Volume: 11, Issue:7, 2016
Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 107, Issue:6, 2016
In vitro effects of co-incubation of blood with artemether/lumefantrine & vitamin C on the viscosity & elasticity of blood.The Indian journal of medical research, , Volume: 143, Issue:5, 2016
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.The Lancet. Infectious diseases, , Volume: 16, Issue:10, 2016
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.Health research policy and systems, , Jun-01, Volume: 14, Issue:1, 2016
[Elimination in South-East Asia? The role of antimalarial drugs].Bulletin de l'Academie nationale de medecine, , Volume: 200, Issue:3, 2016
[Treated with Artemether-Lumefantrine Five Evaluation of P. Falciparum Malaria Cases in Terms of Hyponatremia and Thrombocytopenia].Turkiye parazitolojii dergisi, , Volume: 39, Issue:2, 2015
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Antimicrobial agents and chemotherapy, , Dec-14, Volume: 60, Issue:3, 2015
Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine.Expert review of anti-infective therapy, , Volume: 13, Issue:8, 2015
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:12, 2015
Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:2, 2015
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.BMC medicine, , Sep-18, Volume: 13, 2015
The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:3, 2015
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:10, 2015
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.Antimicrobial agents and chemotherapy, , Volume: 58, Issue:12, 2014
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews, , Mar-04, Issue:3, 2014
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.Journal of biomolecular screening, , Volume: 19, Issue:6, 2014
Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar.The Journal of antimicrobial chemotherapy, , Volume: 69, Issue:8, 2014
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.The American journal of tropical medicine and hygiene, , Volume: 91, Issue:4, 2014
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.Malaria journal, , Sep-19, Volume: 13, 2014
Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania.Malaria journal, , Sep-20, Volume: 13, 2014
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Nature communications, , Nov-26, Volume: 5, 2014
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.PloS one, , Volume: 9, Issue:12, 2014
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.PLoS medicine, , Volume: 11, Issue:12, 2014
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:10, 2013
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 18, Issue:5, 2013
Modulation of PF10_0355 (MSPDBL2) alters Plasmodium falciparum response to antimalarial drugs.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:7, 2013
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.Antimicrobial agents and chemotherapy, , Volume: 57, Issue:7, 2013
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.PloS one, , Volume: 8, Issue:5, 2013
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.The Southeast Asian journal of tropical medicine and public health, , Volume: 44 Suppl 1, 2013
Are artemisinin-based combination therapies effective against Plasmodium malariae?The Journal of antimicrobial chemotherapy, , Volume: 68, Issue:6, 2013
Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.PloS one, , Volume: 8, Issue:1, 2013
Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.Clinical pharmacokinetics, , Volume: 52, Issue:3, 2013
Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Expert opinion on pharmacotherapy, , Volume: 14, Issue:5, 2013
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 56, Issue:10, 2013
Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial.Revista da Sociedade Brasileira de Medicina Tropical, , Volume: 45, Issue:6, 2012
Increased urinary frequency: an unusual presentation of Plasmodium falciparum malaria.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 23, Issue:4, 2012
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Malaria journal, , Aug-22, Volume: 11, 2012
Falciparum--the masquerader.JPMA. The Journal of the Pakistan Medical Association, , Volume: 62, Issue:1, 2012
Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 86, Issue:3, 2012
Successful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.The American journal of tropical medicine and hygiene, , Volume: 86, Issue:3, 2012
Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique.Colloids and surfaces. B, Biointerfaces, , Jun-15, Volume: 95, 2012
Detecting adenosine triphosphatase 6 (pfATP6) point mutations that may be associated with Plasmodium falciparum resistance to artemisinin: prevalence at baseline, before policy change in Uganda.Tanzania journal of health research, , Volume: 13, Issue:1, 2011
Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.Bioorganic & medicinal chemistry, , Dec-15, Volume: 19, Issue:24, 2011
Automated erythrocytapheresis for severe falciparum malaria.Internal medicine journal, , Volume: 41, Issue:1a, 2011
Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum.PLoS genetics, , Volume: 7, Issue:4, 2011
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.PloS one, , Volume: 6, Issue:5, 2011
Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.Malaria journal, , Jul-08, Volume: 10, 2011
The pharmacogenetics of antimalaria artemisinin combination therapy.Expert opinion on drug metabolism & toxicology, , Volume: 7, Issue:10, 2011
Plasmodium species co-infection as a cause of treatment failure.Travel medicine and infectious disease, , Volume: 9, Issue:6, 2011
Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy.The American journal of tropical medicine and hygiene, , Volume: 85, Issue:6, 2011
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.Malaria journal, , Dec-16, Volume: 10, 2011
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 55, Issue:9, 2011
Artemisinin-based combination therapies and their introduction in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, , Volume: 16, Issue:6, 2010
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.Lancet (London, England), , Apr-24, Volume: 375, Issue:9724, 2010
Pyronaridine-artesunate for uncomplicated falciparum malaria.Lancet (London, England), , Apr-24, Volume: 375, Issue:9724, 2010
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:5, 2010
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 15, Issue:4, 2010
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.Journal of tropical pediatrics, , Volume: 56, Issue:6, 2010
Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial.The Journal of infectious diseases, , Aug-15, Volume: 202, Issue:3, 2010
Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan.Annals of tropical medicine and parasitology, , Volume: 104, Issue:4, 2010
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:11, 2010
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Antimicrobial agents and chemotherapy, , Volume: 54, Issue:3, 2010
Cardiac complication after experimental human malaria infection: a case report.Malaria journal, , Dec-03, Volume: 8, 2009
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.PloS one, , Nov-17, Volume: 4, Issue:11, 2009
Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria.PloS one, , Aug-19, Volume: 4, Issue:8, 2009
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection.British journal of haematology, , Volume: 145, Issue:5, 2009
A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma.Bioanalysis, , Volume: 1, Issue:1, 2009
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial.The Journal of infectious diseases, , Jul-01, Volume: 200, Issue:1, 2009
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:12, 2009
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 53, Issue:9, 2009
A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.The American journal of tropical medicine and hygiene, , Volume: 79, Issue:5, 2008
High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria.Tropical medicine & international health : TM & IH, , Volume: 13, Issue:5, 2008
A trial of combination antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Dec-11, Volume: 359, Issue:24, 2008
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.PloS one, , Jun-11, Volume: 3, Issue:6, 2008
Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children.Chemotherapy, , Volume: 54, Issue:3, 2008
Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 102, Issue:9, 2008
[Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Feb-28, Volume: 26, Issue:1, 2008
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children.Malaria journal, , Aug-09, Volume: 7, 2008
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.Malaria journal, , Sep-16, Volume: 7, 2008
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.PLoS medicine, , Dec-23, Volume: 5, Issue:12, 2008
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?Malaria journal, , Sep-15, Volume: 7, 2008
Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.Wiener klinische Wochenschrift, , Volume: 120, Issue:19-20 Supp, 2008
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.Antimicrobial agents and chemotherapy, , Volume: 52, Issue:6, 2008
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.Malaria journal, , Nov-11, Volume: 6, 2007
In vitro interaction of dihydroartemisin and lumefantrine in clinical field isolates from Bangladesh.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.Wiener klinische Wochenschrift, , Volume: 119, Issue:19-20 Supp, 2007
[Treatment of falciparum malaria with artemether-lumefantrine according to a 5-day schedule: results of a study in 21 patients and recommendations].Nederlands tijdschrift voor geneeskunde, , Oct-06, Volume: 151, Issue:40, 2007
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal.Malaria journal, , Jun-14, Volume: 6, 2007
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:8, 2007
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].Bulletin de la Societe de pathologie exotique (1990), , Volume: 100, Issue:1, 2007
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2, 2007
How much fat is necessary to optimize lumefantrine oral bioavailability?Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2, 2007
In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos).The American journal of tropical medicine and hygiene, , Volume: 76, Issue:2, 2007
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:3, 2007
Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria.Expert opinion on pharmacotherapy, , Volume: 8, Issue:1, 2007
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia.Tropical medicine & international health : TM & IH, , Volume: 11, Issue:12, 2006
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo.Malaria journal, , Nov-24, Volume: 5, 2006
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:4, 2006
Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?Malaria journal, , Oct-04, Volume: 5, 2006
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.The Journal of infectious diseases, , Oct-01, Volume: 194, Issue:7, 2006
Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia.Malaria journal, , Aug-28, Volume: 5, 2006
Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults.Malaria journal, , Aug-21, Volume: 5, 2006
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.Travel medicine and infectious disease, , Volume: 4, Issue:2, 2006
From chloroquine to artemisinin-based combination therapy: the Sudanese experience.Malaria journal, , Jul-31, Volume: 5, 2006
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.Malaria journal, , Jul-19, Volume: 5, 2006
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin.The Journal of infectious diseases, , Aug-15, Volume: 194, Issue:4, 2006
High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola.The American journal of tropical medicine and hygiene, , Volume: 75, Issue:1, 2006
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6, 2006
Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.Malaria journal, , May-16, Volume: 5, 2006
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Jun-01, Volume: 42, Issue:11, 2006
[Malaria: a medical and economic problem].Presse medicale (Paris, France : 1983), , Volume: 35, Issue:4 Pt 1, 2006
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?Tropical medicine & international health : TM & IH, , Volume: 11, Issue:4, 2006
The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan.Annals of tropical medicine and parasitology, , Volume: 100, Issue:1, 2006
Successful treatment of Plasmodium falciparum malaria with a six-dose regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon region of Brazil.The American journal of tropical medicine and hygiene, , Volume: 74, Issue:1, 2006
Malaria: uncomplicated, caused by Plasmodium falciparum.Clinical evidence, , Issue:13, 2005
Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia.East African medical journal, , Volume: 82, Issue:8, 2005
Artemisinin-based combinations.Current opinion in infectious diseases, , Volume: 18, Issue:6, 2005
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa.PLoS medicine, , Volume: 2, Issue:11, 2005
A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.Malaria journal, , Sep-22, Volume: 4, 2005
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 41, Issue:8, 2005
Coartem (artemether-lumefantrine) in Africa: the beginning of the end?The Journal of infectious diseases, , Oct-01, Volume: 192, Issue:7, 2005
Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 99, Issue:10, 2005
Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.Proteomics, , Volume: 5, Issue:7, 2005
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).The Journal of infectious diseases, , Mar-15, Volume: 191, Issue:6, 2005
Coartemether (artemether and lumefantrine): an oral antimalarial drug.Expert review of anti-infective therapy, , Volume: 2, Issue:2, 2004
Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:9, 2004
Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan.Annals of tropical medicine and parasitology, , Volume: 98, Issue:6, 2004
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].Tropical medicine & international health : TM & IH, , Volume: 9, Issue:6, 2004
In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand.Wiener klinische Wochenschrift, , Volume: 116 Suppl 4, 2004
Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda.The American journal of tropical medicine and hygiene, , Volume: 71, Issue:5, 2004
Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic.Tropical medicine & international health : TM & IH, , Volume: 9, Issue:11, 2004
Efficacy of artemether-lumefantrine treatment in patients with acute uncomplicated Falciparum malaria in Mayotte, a French collectivity of the Comoros Archipelago.Parasite (Paris, France), , Volume: 11, Issue:3, 2004
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Oct-15, Volume: 39, Issue:8, 2004
Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand.The Southeast Asian journal of tropical medicine and public health, , Volume: 34, Issue:3, 2003
Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand.The Southeast Asian journal of tropical medicine and public health, , Volume: 34, Issue:2, 2003
Artemether-lumefantrine for treating uncomplicated falciparum malaria.The Cochrane database of systematic reviews, , Issue:2, 2003
The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria.Fundamental & clinical pharmacology, , Volume: 17, Issue:2, 2003
[Riamet: a new antimalarial for curative treatment of malaria].Medecine tropicale : revue du Corps de sante colonial, , Volume: 62, Issue:5, 2002
In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether.British journal of clinical pharmacology, , Volume: 49, Issue:5, 2000
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 44, Issue:3, 2000
[Clinical comparative trial of co-artemether and benflumetol (two formulations) in the treatment of falciparum malaria].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Volume: 18, Issue:3, 2000
No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.The American journal of tropical medicine and hygiene, , Volume: 61, Issue:6, 1999
Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.International journal of clinical pharmacology research, , Volume: 19, Issue:2, 1999
Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria.International journal of antimicrobial agents, , Volume: 12, Issue:2, 1999
A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand.The American journal of tropical medicine and hygiene, , Volume: 60, Issue:2, 1999
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs.Antimicrobial agents and chemotherapy, , Volume: 43, Issue:2, 1999
Positioning, labelling, and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team.Medecine tropicale : revue du Corps de sante colonial, , Volume: 58, Issue:3 Suppl, 1998
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.Tropical medicine & international health : TM & IH, , Volume: 3, Issue:6, 1998
A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.The American journal of tropical medicine and hygiene, , Volume: 58, Issue:5, 1998
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.Antimicrobial agents and chemotherapy, , Volume: 42, Issue:1, 1998
Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697.The Journal of infectious diseases, , Volume: 176, Issue:4, 1997
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.The American journal of tropical medicine and hygiene, , Volume: 64, Issue:5-6
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:5
An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:4
The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol).Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 92, Issue:5
Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack.Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 97, Issue:4
[Drug resistant tropical malaria in the Republic of Guinea (West Africa)].Meditsinskaia parazitologiia i parazitarnye bolezni, , Issue:2
Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial.Lancet (London, England), , Volume: 365, Issue:9469
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.Lancet (London, England), , Volume: 365, Issue:9469
Comparison of effectiveness of two different artemisinin-based combination therapies in an area with high seasonal transmission of malaria in Burkina FasoAnnals of parasitology, , Volume: 63, Issue:2
Analytic Study In Patients Presenting To A Tertiary Care Hospital Regarding The Artemether-Lumefantrine Induced Qtc Interval Changes In ECG.Journal of Ayub Medical College, Abbottabad : JAMC, , Volume: 29, Issue:1
Severe acute respiratory distress syndrome secondary to Plasmodium vivax malaria.JPMA. The Journal of the Pakistan Medical Association, , Volume: 66, Issue:3, 2016
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.Antimicrobial agents and chemotherapy, , Volume: 60, Issue:12, 2016
Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8, 2015
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.The Southeast Asian journal of tropical medicine and public health, , Volume: 44 Suppl 1, 2013
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 56, Issue:10, 2013
Hemophagocytic syndrome associated with severe Plasmodium vivax malaria in a child in Bikaner (northwestern India).Journal of vector borne diseases, , Volume: 50, Issue:4, 2013
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.PloS one, , Volume: 8, Issue:5, 2013
Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
A trial of combination antimalarial therapies in children from Papua New Guinea.The New England journal of medicine, , Dec-11, Volume: 359, Issue:24, 2008
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.The Korean journal of parasitology, , Volume: 45, Issue:2, 2007
Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand.Wiener klinische Wochenschrift, , Volume: 116 Suppl 4, 2004
In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand.Wiener klinische Wochenschrift, , Volume: 115 Suppl 3, 2003
[Observation on efficacy of artemether compound against vivax malaria].Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, , Volume: 17, Issue:3, 1999
Safety/Toxicity (20)
| Article | Year |
|---|
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
PloS one, , Volume: 14, Issue:9 | 2019 |
Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.
Malaria journal, , Jun-24, Volume: 18, Issue:1 | 2019 |
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
The Lancet. Infectious diseases, , Volume: 17, Issue:5 | 2017 |
Genotoxic effects of the antimalarial drug lumefantrine in human lymphocytes in vitro and computational prediction of the mechanism associated with its interaction with DNA.
Environmental and molecular mutagenesis, , Volume: 56, Issue:6 | 2015 |
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.
PloS one, , Volume: 9, Issue:12 | 2014 |
Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania.
Malaria journal, , Sep-20, Volume: 13 | 2014 |
Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 23, Issue:3 | 2014 |
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.
Drug safety, , Volume: 36, Issue:9 | 2013 |
Neurotoxicity assessment of artemether in juvenile rats.
Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 98, Issue:2 | 2013 |
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria.
Tropical medicine & international health : TM & IH, , Volume: 18, Issue:5 | 2013 |
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Malaria journal, , Dec-16, Volume: 10 | 2011 |
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
Lancet (London, England), , Apr-24, Volume: 375, Issue:9724 | 2010 |
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.
Malaria journal, , Sep-16, Volume: 7 | 2008 |
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.
Malaria journal, , Nov-11, Volume: 6 | 2007 |
Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults.
Malaria journal, , Aug-21, Volume: 5 | 2006 |
Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.
Travel medicine and infectious disease, , Volume: 4, Issue:2 | 2006 |
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.
The American journal of tropical medicine and hygiene, , Volume: 74, Issue:6 | 2006 |
Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia.
East African medical journal, , Volume: 82, Issue:8 | 2005 |
An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug.
Transactions of the Royal Society of Tropical Medicine and Hygiene, , Volume: 94, Issue:4 | |
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.
Tropical medicine & international health : TM & IH, , Volume: 3, Issue:6 | 1998 |
Long-term Use (1)
Pharmacokinetics (41)
| Article | Year |
|---|
The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
British journal of clinical pharmacology, , Volume: 88, Issue:2 | 2022 |
Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 34, Issue:9 | 2020 |
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5 | 2020 |
Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
PloS one, , Volume: 12, Issue:10 | 2017 |
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.
Malaria journal, , 07-03, Volume: 16, Issue:1 | 2017 |
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.
Antimicrobial agents and chemotherapy, , Volume: 61, Issue:9 | 2017 |
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Antimicrobial agents and chemotherapy, , Volume: 60, Issue:12 | 2016 |
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8 | 2016 |
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
Antimicrobial agents and chemotherapy, , Dec-14, Volume: 60, Issue:3 | 2015 |
Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.
Scientific reports, , Nov-25, Volume: 5 | 2015 |
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:10 | 2015 |
Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8 | 2015 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Malaria journal, , Apr-25, Volume: 14 | 2015 |
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
British journal of clinical pharmacology, , Volume: 79, Issue:4 | 2015 |
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.
Antimicrobial agents and chemotherapy, , Volume: 57, Issue:10 | 2013 |
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
HIV medicine, , Volume: 14, Issue:7 | 2013 |
Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.
Clinical pharmacokinetics, , Volume: 52, Issue:3 | 2013 |
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
Malaria journal, , Aug-22, Volume: 11 | 2012 |
Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.
Biopharmaceutics & drug disposition, , Volume: 33, Issue:4 | 2012 |
Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.
Bioanalysis, , Volume: 4, Issue:2 | 2012 |
Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.
Malaria journal, , Oct-10, Volume: 10 | 2011 |
Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Clinical pharmacokinetics, , Nov-01, Volume: 50, Issue:11 | 2011 |
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
Antimicrobial agents and chemotherapy, , Volume: 55, Issue:11 | 2011 |
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.
Antimicrobial agents and chemotherapy, , Volume: 55, Issue:9 | 2011 |
Pharmacodynamic interaction between lumefantrine and desbutyl-benflumetol in Plasmodium falciparum in vitro.
Wiener klinische Wochenschrift, , Volume: 122 Suppl 3 | 2010 |
Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of artemether and lumefantrine in human plasma: application for a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis, , Jan-05, Volume: 54, Issue:1 | 2011 |
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.
Antimicrobial agents and chemotherapy, , Volume: 54, Issue:11 | 2010 |
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1 | 2010 |
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
Antimicrobial agents and chemotherapy, , Volume: 53, Issue:9 | 2009 |
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
Journal of acquired immune deficiency syndromes (1999), , Aug-01, Volume: 51, Issue:4 | 2009 |
Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Apr-15, Volume: 877, Issue:11-12 | 2009 |
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2 | 2007 |
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
European journal of clinical pharmacology, , Volume: 62, Issue:12 | 2006 |
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.
Malaria journal, , Jul-19, Volume: 5 | 2006 |
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
British journal of clinical pharmacology, , Volume: 54, Issue:5 | 2002 |
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.
The American journal of tropical medicine and hygiene, , Volume: 64, Issue:5-6 | |
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.
Antimicrobial agents and chemotherapy, , Volume: 44, Issue:3 | 2000 |
Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.
International journal of clinical pharmacology research, , Volume: 19, Issue:2 | 1999 |
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clinical pharmacokinetics, , Volume: 37, Issue:2 | 1999 |
Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria.
International journal of antimicrobial agents, , Volume: 12, Issue:2 | 1999 |
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
British journal of clinical pharmacology, , Volume: 46, Issue:6 | 1998 |
Bioavailability (29)
| Article | Year |
|---|
Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy.
Journal of pharmaceutical sciences, , Volume: 112, Issue:8 | 2023 |
Lumefantrine solid dispersions with piperine for the enhancement of solubility, bioavailability and anti-parasite activity.
International journal of pharmaceutics, , Nov-25, Volume: 628 | 2022 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Clinical pharmacology and therapeutics, , Volume: 113, Issue:3 | 2023 |
Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Challenging Case of Lumefantrine-PAA.
Journal of pharmaceutical sciences, , Volume: 110, Issue:11 | 2021 |
Co-precipitates of lumefantrine-Eudragit E PO for dissolution improvement.
Annales pharmaceutiques francaises, , Volume: 80, Issue:1 | 2022 |
Enantioselective in vitro ADME, absolute oral bioavailability, and pharmacokinetics of (-)-lumefantrine and (+)-lumefantrine in mice.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 51, Issue:2 | 2021 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46 | 2019 |
Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
Journal of translational medicine, , 06-14, Volume: 17, Issue:1 | 2019 |
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.
Antimicrobial agents and chemotherapy, , Volume: 61, Issue:9 | 2017 |
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8 | 2016 |
Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
International journal of pharmaceutics, , Sep-10, Volume: 511, Issue:1 | 2016 |
Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles.
Drug development and industrial pharmacy, , Volume: 42, Issue:10 | 2016 |
In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 97, Issue:Pt A | 2015 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Malaria journal, , Apr-25, Volume: 14 | 2015 |
Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study.
Malaria journal, , Apr-22, Volume: 14 | 2015 |
Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine.
Antimicrobial agents and chemotherapy, , Volume: 58, Issue:1 | 2014 |
Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product.
Malaria journal, , May-30, Volume: 12 | 2013 |
Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO.
European journal of clinical pharmacology, , Volume: 68, Issue:12 | 2012 |
Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.
Biopharmaceutics & drug disposition, , Volume: 33, Issue:4 | 2012 |
Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique.
Colloids and surfaces. B, Biointerfaces, , Jun-15, Volume: 95 | 2012 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061 | 2011 |
Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.
Malaria journal, , Oct-10, Volume: 10 | 2011 |
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
Antimicrobial agents and chemotherapy, , Volume: 55, Issue:11 | 2011 |
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.
Tropical medicine & international health : TM & IH, , Volume: 15, Issue:4 | 2010 |
Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper.
Journal of pharmaceutical and biomedical analysis, , Oct-18, Volume: 45, Issue:2 | 2007 |
How much fat is necessary to optimize lumefantrine oral bioavailability?
Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2 | 2007 |
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.
Antimicrobial agents and chemotherapy, , Volume: 44, Issue:3 | 2000 |
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
British journal of clinical pharmacology, , Volume: 46, Issue:6 | 1998 |
Dosage (40)
| Article | Year |
|---|
Knowledge and practices of private pharmacy auxiliaries on malaria in Abidjan, Côte d'Ivoire.
Malaria journal, , Nov-02, Volume: 22, Issue:1 | 2023 |
Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy.
Journal of pharmaceutical sciences, , Volume: 112, Issue:8 | 2023 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Clinical pharmacology and therapeutics, , Volume: 113, Issue:3 | 2023 |
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
The Lancet. Infectious diseases, , Volume: 23, Issue:1 | 2023 |
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 02-08, Volume: 76, Issue:3 | 2023 |
Characterization of solid lipid dispersions prepared by hot fusion containing a double-fixed dose combination of artemether and lumefantrine.
Drug development and industrial pharmacy, , Volume: 46, Issue:8 | 2020 |
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Journal of acquired immune deficiency syndromes (1999), , 02-01, Volume: 83, Issue:2 | 2020 |
Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
Journal of translational medicine, , 06-14, Volume: 17, Issue:1 | 2019 |
Lumefantrine and o-choline - Parasite metabolism specific drug molecules inhibited in vitro growth of Theileria equi and Babesia caballi in MASP culture system.
Ticks and tick-borne diseases, , Volume: 10, Issue:3 | 2019 |
The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound.
Expert opinion on investigational drugs, , Volume: 27, Issue:10 | 2018 |
Level A in vitro-in vivo correlation: Application to establish a dissolution test for artemether and lumefantrine tablets.
Journal of pharmaceutical and biomedical analysis, , Jun-05, Volume: 155 | 2018 |
Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
PloS one, , Volume: 12, Issue:10 | 2017 |
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
The Journal of infectious diseases, , Oct-15, Volume: 214, Issue:8 | 2016 |
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.
The Lancet. Infectious diseases, , Volume: 16, Issue:10 | 2016 |
Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
International journal of pharmaceutics, , Sep-10, Volume: 511, Issue:1 | 2016 |
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
BMC infectious diseases, , Jan-27, Volume: 16 | 2016 |
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.
BMC medicine, , Sep-18, Volume: 13 | 2015 |
Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.
Antimicrobial agents and chemotherapy, , Volume: 59, Issue:8 | 2015 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Malaria journal, , Apr-25, Volume: 14 | 2015 |
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.
PLoS medicine, , Volume: 11, Issue:12 | 2014 |
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
British journal of clinical pharmacology, , Volume: 79, Issue:4 | 2015 |
Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.
Antimicrobial agents and chemotherapy, , Volume: 57, Issue:10 | 2013 |
Neurotoxicity assessment of artemether in juvenile rats.
Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 98, Issue:2 | 2013 |
Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.
Clinical pharmacokinetics, , Volume: 52, Issue:3 | 2013 |
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Malaria journal, , Dec-16, Volume: 10 | 2011 |
The pharmacogenetics of antimalaria artemisinin combination therapy.
Expert opinion on drug metabolism & toxicology, , Volume: 7, Issue:10 | 2011 |
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.
Antimicrobial agents and chemotherapy, , Volume: 55, Issue:9 | 2011 |
Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.
The American journal of tropical medicine and hygiene, , Volume: 83, Issue:4 | 2010 |
Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan.
Annals of tropical medicine and parasitology, , Volume: 104, Issue:4 | 2010 |
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Antimicrobial agents and chemotherapy, , Volume: 54, Issue:1 | 2010 |
Community effectiveness of artemisinin-based combination therapy for malaria in rural southwestern Nigeria.
International quarterly of community health education, , Volume: 29, Issue:1 | |
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.
PloS one, , Jun-11, Volume: 3, Issue:6 | 2008 |
The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya.
Tropical medicine & international health : TM & IH, , Volume: 13, Issue:4 | 2008 |
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2 | 2007 |
How much fat is necessary to optimize lumefantrine oral bioavailability?
Tropical medicine & international health : TM & IH, , Volume: 12, Issue:2 | 2007 |
Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?
Malaria journal, , Oct-04, Volume: 5 | 2006 |
Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.
Malaria journal, , Jul-19, Volume: 5 | 2006 |
Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda.
The American journal of tropical medicine and hygiene, , Volume: 71, Issue:5 | 2004 |
Efficacy of artemether-lumefantrine treatment in patients with acute uncomplicated Falciparum malaria in Mayotte, a French collectivity of the Comoros Archipelago.
Parasite (Paris, France), , Volume: 11, Issue:3 | 2004 |
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
Clinical pharmacokinetics, , Volume: 37, Issue:2 | 1999 |
Interactions (4)
| Article | Year |
|---|
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Antimicrobial agents and chemotherapy, , 04-21, Volume: 64, Issue:5 | 2020 |
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.
Antimicrobial agents and chemotherapy, , Volume: 63, Issue:2 | 2019 |
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1 | 2012 |
The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria.
Fundamental & clinical pharmacology, , Volume: 17, Issue:2 | 2003 |